1
|
Duffaud F, Blay JY, Le Cesne A, Chevreau C, Boudou-Rouquette P, Kalbacher E, Penel N, Perrin C, Laurence V, Bompas E, Saada-Bouzid E, Delcambre C, Bertucci F, Cancel M, Schiffler C, Monard L, Bouvier C, Vidal V, Gaspar N, Chabaud S. Regorafenib in patients with advanced Ewing sarcoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre Phase II study. Br J Cancer 2023; 129:1940-1948. [PMID: 37914801 PMCID: PMC10703915 DOI: 10.1038/s41416-023-02413-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2022] [Revised: 07/23/2023] [Accepted: 08/21/2023] [Indexed: 11/03/2023] Open
Abstract
BACKGROUND The REGOBONE multi-cohort study explored the efficacy and safety of regorafenib for patients with advanced bone sarcomas; this report details the Ewing sarcoma (ES) cohort. METHODS Patients with relapsed ES progressing despite prior standard therapy, were randomised (2:1) to receive regorafenib or placebo. Patients on placebo could crossover to receive regorafenib after centrally confirmed progression. The primary endpoint was the progression-free rate at 8 weeks. With one-sided α of 0.05, and 80% power, at least 14/24 progression-free patients at 8 weeks were needed for success. RESULTS From September 2014 to November 2019, 41 patients were accrued. 36 patients were evaluable for efficacy: 23 on regorafenib and 13 on placebo. Thirteen patients (56%; one-sided 95% CI [37.5%-[)) were progression-free at 8 weeks on regorafenib vs. 1 (7.7%; 95% CI [0.4%-[) on placebo. Median PFS was 11.4 weeks on regorafenib, and 3.9 weeks on placebo. Ten placebo patients crossed over to receive regorafenib after progression. The most common grade ≥3 regorafenib-related adverse events were pain (22%), asthenia (17%), thrombocytopenia (13%) and diarrhoea (13%). CONCLUSION Although the primary endpoint was not met statistically in this randomised cohort, there is evidence to suggest that regorafenib might modestly delay tumour progression in relapsed ES after failure of prior chemotherapy.
Collapse
Affiliation(s)
- Florence Duffaud
- APHM Hopital La Timone, Medical Oncology Unit, and Aix-Marseille University (AMU), Marseille, France.
| | - Jean-Yves Blay
- Medical Oncology Department, Centre Léon Bérard, Lyon, France
| | - Axel Le Cesne
- Medical Oncology Department, Gustave Roussy, Villejuif, France
| | - Christine Chevreau
- Medical Oncology Department, Institut Universitaire de Cancérologie de Toulouse, Oncopole, Toulouse, France
| | | | - Elsa Kalbacher
- Medical Oncology Department, CHU J Minjoz, Besançon, France
| | - Nicolas Penel
- Medical Oncology Department, Centre Oscar Lambret and Lille University Hospital, Lille, France
| | | | | | - Emmanuelle Bompas
- Medical Oncology Department, Centre René Gauduchau, Saint Herblain, France
| | - Esma Saada-Bouzid
- Medical Oncology Department, Centre Antoine Lacassagne, Nice, France
| | | | - François Bertucci
- Medical Oncology Department, Institut Paoli-Calmettes, Marseille, France
| | - Mathilde Cancel
- Medical Oncology Department, Centre Hospitalier Régional Universitaire Bretonneau, Tours, France
| | | | | | - Corinne Bouvier
- APHM Hopital La Timone, Pathology Department, and Aix-Marseille University, Marseille, France
| | - Vincent Vidal
- APHM Hopital La Timone, Radiology Department, and Aix-Marseille University Marseille, Marseille, France
| | - Nathalie Gaspar
- Department of Oncology for Child and Adolescent, Gustave Roussy Cancer Campus, Villejuif, France
| | - Sylvie Chabaud
- Department of Statistics, Centre Léon Bérard, Lyon, France
| |
Collapse
|
2
|
Le Cesne A, Chevreau C, Perrin C, Italiano A, Hervieu A, Blay JY, Piperno-Neumann S, Saada-Bouzid E, Bertucci F, Firmin N, Kalbacher E, Narciso B, Schiffler C, Yara S, Jimenez M, Bouvier C, Vidal V, Chabaud S, Duffaud F. Regorafenib in patients with relapsed advanced or metastatic chordoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre phase II study. ESMO Open 2023; 8:101569. [PMID: 37285716 DOI: 10.1016/j.esmoop.2023.101569] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2023] [Revised: 04/10/2023] [Accepted: 04/24/2023] [Indexed: 06/09/2023] Open
Abstract
BACKGROUND REGOBONE multicohort study explored the efficacy and safety of regorafenib for patients with advanced bone sarcomas; this report details the cohort of patients with relapsed advanced or metastatic chordoma. METHODS Patients with relapsed chordoma progressing despite 0-2 prior lines of systemic therapy, were randomised (2 : 1) to receive regorafenib (160 mg/day, 21/28 days) or placebo. Patients on placebo could cross over to receive regorafenib after centrally-confirmed progression. The primary endpoint was the progression-free rate at 6 months (PFR-6) (by RECIST 1.1). With one-sided α of 0.05, and 80% power, at least 10/24 progression-free patients at 6 months (PFR-6) were needed for success. RESULTS From March 2016 to February 2020, 27 patients were enrolled. A total of 23 patients were assessable for efficacy: 7 on placebo, 16 on regorafenib, 16 were men, median age was 66 (32-85) years. At 6 months, in the regorafenib arm, 1 patient was not assessable, 6/14 were non-progressive (PFR-6: 42.9%; one-sided 95% CI = 20.6) 3/14 discontinued regorafenib due to toxicity; and in the placebo arm, 2/5 patients were non-progressive (PFR-6: 40.0%; one-sided 95% CI = 7.6), 2 were non-assessable. Median progression-free survival was 8.2 months (95% CI 4.5-12.9 months) on regorafenib and 10.1 months (95% CI 0.8 months-non evaluable [NE]) on placebo. Median overall survival rates were 28.3 months (95% CI 14.8 months-NE) on regorafenib but not reached in placebo arm. Four placebo patients crossed over to receive regorafenib after centrally-confirmed progression. The most common grade ≥3 regorafenib-related adverse events were hand-foot skin reaction (22%), hypertension (22%), pain (22%), and diarrhoea (17%), with no toxic death. CONCLUSION This study failed to show any signal of benefit for regorafenib in patients with advanced/metastatic recurrent chordoma.
Collapse
Affiliation(s)
- A Le Cesne
- Medical Oncology Department, Gustave Roussy, Villejuif
| | - C Chevreau
- Medical Oncology Department, Institut Universitaire de Cancérologie de Toulouse, Oncopole, Toulouse
| | - C Perrin
- Medical Oncology Unit, Centre Eugène Marquis, Rennes
| | - A Italiano
- Medical Oncology Department, Institut Bergonié, Bordeaux
| | - A Hervieu
- Medical Oncology Department, Centre Georges Francois Leclerc, Dijon
| | - J Y Blay
- Medical Oncology Department, Centre Léon Bérard, Lyons. https://twitter.com/jeanyvesblay
| | | | - E Saada-Bouzid
- Medical Oncology Department, Centre Antoine Lacassagne, Nice
| | - F Bertucci
- Medical Oncology Department, Institut Paoli Calmettes, Marseille
| | - N Firmin
- Medical Oncologie Department, Centre Valdorelle, Montpellier
| | - E Kalbacher
- Medical Oncology Department, CHU J Minjoz, Besançon
| | - B Narciso
- Medical Oncology Department, CHU Bretonneau, Tours
| | - C Schiffler
- Department of Statistics, Centre Léon Bérard, Lyons
| | | | | | - C Bouvier
- Aix Marseille Univ, APHM Hopital La Timone, Pathology Department, Marseille
| | - V Vidal
- Aix Marseille Univ, APHM Hopital La Timone, Radiology Department, Marseille
| | - S Chabaud
- Department of Statistics, Centre Léon Bérard, Lyons
| | - F Duffaud
- Aix Marseille University (AMU), APHM Hopital La Timone, Medical Oncology Unit, APHM, Marseille, France.
| |
Collapse
|
3
|
Haikal C, Beucler N, Fuentes S, Bouvier C, Le Corroller T. Intractable low-back pain in a patient with history of multiple neoplasms. Skeletal Radiol 2023; 52:137-139. [PMID: 35792955 DOI: 10.1007/s00256-022-04115-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/12/2022] [Revised: 06/23/2022] [Accepted: 06/28/2022] [Indexed: 02/02/2023]
Affiliation(s)
- Christelle Haikal
- Radiology Department, APHM, Hôpital Sainte-Marguerite, 270 Bd de Sainte-Marguerite, 13009, Marseille, France
| | - Nathan Beucler
- Neurosurgery Department, APHM, Hôpital La Timone, 13005, Marseille, France
| | - Stéphane Fuentes
- Neurosurgery Department, APHM, Hôpital La Timone, 13005, Marseille, France
| | - Corinne Bouvier
- Pathology Department, APHM, Hôpital La Timone, 13005, Marseille, France
| | - Thomas Le Corroller
- Radiology Department, APHM, Hôpital Sainte-Marguerite, 270 Bd de Sainte-Marguerite, 13009, Marseille, France. .,ISM UMR 7287, Aix Marseille University, CNRS, Marseille, France.
| |
Collapse
|
4
|
Haikal C, Beucler N, Fuentes S, Bouvier C, Le Corroller T. Intractable low-back pain in a patient with history of multiple neoplasms. Skeletal Radiol 2023; 52:111-112. [PMID: 35804162 DOI: 10.1007/s00256-022-04114-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/12/2022] [Revised: 06/23/2022] [Accepted: 06/28/2022] [Indexed: 02/02/2023]
Affiliation(s)
| | | | | | | | - Thomas Le Corroller
- Radiology Department, APHM, Marseille, France.
- Aix Marseille University, CNRS, ISM UMR 7287, Marseille, France.
| |
Collapse
|
5
|
de Nonneville A, Salas S, Bertucci F, Sobinoff AP, Adélaïde J, Guille A, Finetti P, Noble JR, Churikov D, Chaffanet M, Lavit E, Pickett HA, Bouvier C, Birnbaum D, Reddel RR, Géli V. TOP3A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT. EMBO Mol Med 2022; 14:e15859. [PMID: 35920001 PMCID: PMC9549729 DOI: 10.15252/emmm.202215859] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2022] [Revised: 07/13/2022] [Accepted: 07/14/2022] [Indexed: 02/05/2023] Open
Abstract
In some types of cancer, telomere length is maintained by the alternative lengthening of telomeres (ALT) mechanism. In many ALT cancers, the α-thalassemia/mental retardation syndrome X-linked (ATRX) gene is mutated leading to the conclusion that the ATRX complex represses ALT. Here, we report that most high-grade pediatric osteosarcomas maintain their telomeres by ALT, and that the majority of these ALT tumors are ATRX wild-type (wt) and instead carry an amplified 17p11.2 chromosomal region containing TOP3A. We found that TOP3A was overexpressed in the ALT-positive ATRX-wt tumors consistent with its amplification. We demonstrated the functional significance of these results by showing that TOP3A overexpression in ALT cancer cells countered ATRX-mediated ALT inhibition and that TOP3A knockdown disrupted the ALT phenotype in ATRX-wt cells. Moreover, we report that TOP3A is required for proper BLM localization and promotes ALT DNA synthesis in ALT cell lines. Collectively, our results identify TOP3A as a major ALT player and potential therapeutic target.
Collapse
Affiliation(s)
- Alexandre de Nonneville
- Marseille Cancer Research Centre (CRCM), Inserm U1068, CNRS UMR7258, Institut Paoli‐Calmettes, Team « Telomere and Chromatin ». Equipe labellisée Ligue Nationale Contre Le CancerAix‐Marseille UnivMarseilleFrance,Cancer Research Unit, Faculty of Medicine and Health, Children's Medical Research InstituteUniversity of SydneyWestmeadNSWAustralia,Predictive Oncology Laboratory, Marseille Cancer Research Centre (CRCM), Inserm U1068, CNRS UMR7258, Institut Paoli‐CalmettesAix‐Marseille UniversityMarseilleFrance,Department of Medical Oncology, CRCM, CNRS, INSERM, Institut Paoli‐CalmettesAix‐Marseille UnivMarseilleFrance
| | - Sébastien Salas
- Department of Medical OncologyAssistance Publique Hôpitaux de Marseille ‐ Timone HospitalMarseilleFrance
| | - François Bertucci
- Predictive Oncology Laboratory, Marseille Cancer Research Centre (CRCM), Inserm U1068, CNRS UMR7258, Institut Paoli‐CalmettesAix‐Marseille UniversityMarseilleFrance,Department of Medical Oncology, CRCM, CNRS, INSERM, Institut Paoli‐CalmettesAix‐Marseille UnivMarseilleFrance
| | - Alexander P Sobinoff
- Telomere Length Regulation Unit, Faculty of Medicine and Health, Children's Medical Research InstituteUniversity of SydneyWestmeadNSWAustralia
| | - José Adélaïde
- Predictive Oncology Laboratory, Marseille Cancer Research Centre (CRCM), Inserm U1068, CNRS UMR7258, Institut Paoli‐CalmettesAix‐Marseille UniversityMarseilleFrance
| | - Arnaud Guille
- Predictive Oncology Laboratory, Marseille Cancer Research Centre (CRCM), Inserm U1068, CNRS UMR7258, Institut Paoli‐CalmettesAix‐Marseille UniversityMarseilleFrance
| | - Pascal Finetti
- Predictive Oncology Laboratory, Marseille Cancer Research Centre (CRCM), Inserm U1068, CNRS UMR7258, Institut Paoli‐CalmettesAix‐Marseille UniversityMarseilleFrance
| | - Jane R Noble
- Cancer Research Unit, Faculty of Medicine and Health, Children's Medical Research InstituteUniversity of SydneyWestmeadNSWAustralia
| | - Dimitri Churikov
- Marseille Cancer Research Centre (CRCM), Inserm U1068, CNRS UMR7258, Institut Paoli‐Calmettes, Team « Telomere and Chromatin ». Equipe labellisée Ligue Nationale Contre Le CancerAix‐Marseille UnivMarseilleFrance
| | - Max Chaffanet
- Predictive Oncology Laboratory, Marseille Cancer Research Centre (CRCM), Inserm U1068, CNRS UMR7258, Institut Paoli‐CalmettesAix‐Marseille UniversityMarseilleFrance
| | - Elise Lavit
- Department of Medical OncologyAssistance Publique Hôpitaux de Marseille ‐ Timone HospitalMarseilleFrance
| | - Hilda A Pickett
- Telomere Length Regulation Unit, Faculty of Medicine and Health, Children's Medical Research InstituteUniversity of SydneyWestmeadNSWAustralia
| | - Corinne Bouvier
- Department of PathologyAssistance Publique Hôpitaux de Marseille ‐ Timone HospitalMarseilleFrance
| | - Daniel Birnbaum
- Predictive Oncology Laboratory, Marseille Cancer Research Centre (CRCM), Inserm U1068, CNRS UMR7258, Institut Paoli‐CalmettesAix‐Marseille UniversityMarseilleFrance
| | - Roger R Reddel
- Cancer Research Unit, Faculty of Medicine and Health, Children's Medical Research InstituteUniversity of SydneyWestmeadNSWAustralia
| | - Vincent Géli
- Marseille Cancer Research Centre (CRCM), Inserm U1068, CNRS UMR7258, Institut Paoli‐Calmettes, Team « Telomere and Chromatin ». Equipe labellisée Ligue Nationale Contre Le CancerAix‐Marseille UnivMarseilleFrance
| |
Collapse
|
6
|
Nihous H, Baud J, Azmani R, Michot A, Perret R, Mayeur L, de Pinieux G, Milin S, Angot E, Duquenne S, Geneste D, Lucchesi C, Le Loarer F, Bouvier C. Clinicopathologic and Molecular Study of Hybrid Nerve Sheath Tumors Reveals Their Common Association With Fusions Involving VGLL3. Am J Surg Pathol 2022; 46:591-602. [PMID: 35256555 DOI: 10.1097/pas.0000000000001858] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
A subset of benign peripheral nerve sheath tumors are "hybrid" combining several lines of differentiation, most often schwannian and perineurial features. The pathogenesis of these tumors was poorly described until the recent discovery of recurrent VGLL3 rearrangements in hybrid schwannoma/perineuriomas, supporting the hypothesis that this entity represents a distinct subgroup of tumors and not only a morphologic variation of other peripheral nerve sheath tumors. Following this finding, we investigated 10 cases of hybrid peripheral nerve sheath tumors with immunohistochemistry, RNA sequencing, and array comparative genomic hybridization. By light microscopy, 7 tumors were hybrid schwannoma/perineurioma tumors, and 3 were hybrid schwannoma/neurofibroma. Most cases of hybrid schwannoma/perineuriomas displayed VGLL3 rearrangements fused in 5' either to CHD7 or CHD9 (n=6/7) and had simple diploid genetic profiles with few copy number alterations. Compared with a control group composed of 28 tumors associated with varied neural phenotypes, all VGLL3-fused tumors clustered together by transcriptomic analysis. In contrast, 1 case of hybrid schwannoma/perineurioma tumor harbored a CDH9-ZFHX3 fusion, a prominent perineurial component identified by immunohistochemistry and clustered with perineuriomas. No recurrent genetic alteration was seen in the 3 hybrid schwannoma/neurofibromas. To summarize, this study confirms and expands the recent findings on hybrid schwannoma/perineurioma, highlighting the predominance of VGLL3 fusions in these tumors.
Collapse
Affiliation(s)
- Hugo Nihous
- Department of Pathology, AP-HM La Timone, Marseille
| | - Jessica Baud
- INSERM U1218, ACTION, Comprehensive Cancer Center of Bordeaux, Bergonie Institute
- Department of Pathology, University of Bordeaux, Talence, France
| | | | - Audrey Michot
- INSERM U1218, ACTION, Comprehensive Cancer Center of Bordeaux, Bergonie Institute
- Surgery
| | | | - Laetitia Mayeur
- Molecular Pathology, Comprehensive Cancer Center of Bordeaux, Bordeaux
| | | | - Serge Milin
- Department of Pathology, Poitiers University Hospital, Poitiers
| | - Emilie Angot
- Department of Pathology, Rouen University Hospital, Rouen
| | | | | | - Carlo Lucchesi
- INSERM U1218, ACTION, Comprehensive Cancer Center of Bordeaux, Bergonie Institute
- Departments of Bioinformatics
| | - Francois Le Loarer
- INSERM U1218, ACTION, Comprehensive Cancer Center of Bordeaux, Bergonie Institute
- Pathology
- Department of Pathology, University of Bordeaux, Talence, France
| | | |
Collapse
|
7
|
Bouvier C, Nihous H, Macagno N. [Soft tissue tumours with FN1 (Fibronectin 1) fusion gene]. Ann Pathol 2022; 42:242-248. [PMID: 35181149 DOI: 10.1016/j.annpat.2022.01.018] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2022] [Revised: 01/31/2022] [Accepted: 01/31/2022] [Indexed: 10/19/2022]
Abstract
Translocations involving FN1 gene have been described in several tumours, which share the presence of a cartilaginous matrix with or without calcifications and a good prognosis. They encompass: soft tissue chondroma, synovial chondromatosis, calcifying aponeurotic fibroma, phosphaturic mesenchymal tumour and a new spectrum of tumours: "the calcified chondroid mesenchymal neoplasms". We review all the clinical, histopathological and molecular data of these tumours and discuss the differential diagnoses.
Collapse
Affiliation(s)
- Corinne Bouvier
- Service d'anatomie pathologique et de neuropathologie, hôpital de la Timone, 264, rue Saint-Pierre, 13385 Marseille cedex 05, France; Inserm MMG, Aix-Marseille Université, Marseille, France.
| | - Hugo Nihous
- Service d'anatomie pathologique et de neuropathologie, hôpital de la Timone, 264, rue Saint-Pierre, 13385 Marseille cedex 05, France
| | - Nicolas Macagno
- Service d'anatomie pathologique et de neuropathologie, hôpital de la Timone, 264, rue Saint-Pierre, 13385 Marseille cedex 05, France; Inserm MMG, Aix-Marseille Université, Marseille, France
| |
Collapse
|
8
|
Miquelestorena-Standley E, Tallegas M, Bouvier C, Larousserie F, Aubert S, Gomez-Brouchet A, Guinebretière JM, Le Loarer F, Galant C, de Pinieux G. [From an optimal management of bone tissue samples to a quality patients' care in 2022 : A new paradigm]. Ann Pathol 2022; 42:202-207. [PMID: 35093248 DOI: 10.1016/j.annpat.2022.01.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2021] [Accepted: 01/04/2022] [Indexed: 10/19/2022]
Abstract
Bone tissue can be involved by primitive or metastatic tumors and requires a specific processing both at the department of pathology and during multidisciplinary meetings. The development of fine-needle percutaneous biopsies and of molecular techniques in bone tumor pathology requires a specific management. Moreover, decalcification of samples is crucial but can be deleterious if not controlled or not appropriate. The aim of this review is to provide recommendations for management and decalcification of bone tumor samples.
Collapse
Affiliation(s)
- Elodie Miquelestorena-Standley
- Service d'anatomie et cytologie pathologiques, CHRU de Tours, hôpital Trousseau, avenue de la République, 37170 Chambray-les-Tours, France; Faculté de médecine, Université de Tours, 10, boulevard Tonnellé, 37000 Tours, France.
| | - Matthias Tallegas
- Service d'anatomie et cytologie pathologiques, CHRU de Tours, hôpital Trousseau, avenue de la République, 37170 Chambray-les-Tours, France; Plateforme de génétique moléculaire des cancers, CHRU de Tours, hôpital Trousseau, avenue de la République, 37170 Chambray-les-Tours, France
| | - Corinne Bouvier
- Service d'anatomie et cytologie pathologiques, CHU de Marseille La Timone, 264, rue Saint-Pierre, 13005 Marseille, France
| | - Frédérique Larousserie
- Service d'anatomie et cytologie pathologiques, Hôpital Cochin, 27, rue du Faubourg Saint-Jacques, 75014 Paris, France
| | - Sébastien Aubert
- Service d'anatomie et cytologie pathologiques, CHU de Lille, 2, avenue Oscar Lambret, 59000 Lille, France
| | - Anne Gomez-Brouchet
- CRB Cancer IUCT-oncopole, 1, avenue Irène Joliot-Curie, 31100 Toulouse, France
| | - Jean-Marc Guinebretière
- Service d'anatomie et cytologie pathologiques, Hôpital Curie, 26, rue d'Ulm, 75005 Paris, France
| | - François Le Loarer
- Service d'anatomie pathologique, Institut Bergonié, 229, cours Argonne, 33000 Bordeaux, France
| | - Christine Galant
- Service d'anatomie et cytologie pathologiques, Cliniques Universitaires Saint-Luc, 10, avenue Hippocrate, 1200 Bruxelles, Belgique
| | - Gonzague de Pinieux
- Service d'anatomie et cytologie pathologiques, CHRU de Tours, hôpital Trousseau, avenue de la République, 37170 Chambray-les-Tours, France; Faculté de médecine, Université de Tours, 10, boulevard Tonnellé, 37000 Tours, France
| |
Collapse
|
9
|
Gomez-Brouchet A, Illac C, Ledoux A, Fortin PY, de Barros S, Vabre C, Despas F, Peries S, Casaroli C, Bouvier C, Aubert S, de Pinieux G, Larousserie F, Galmiche L, Talmont F, Pitson S, Maddelein ML, Cuvillier O. Sphingosine Kinase-1 Is Overexpressed and Correlates with Hypoxia in Osteosarcoma: Relationship with Clinicopathological Parameters. Cancers (Basel) 2022; 14:cancers14030499. [PMID: 35158767 PMCID: PMC8833796 DOI: 10.3390/cancers14030499] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2021] [Revised: 01/14/2022] [Accepted: 01/16/2022] [Indexed: 11/16/2022] Open
Abstract
The Sphingosine kinase-1/Sphingosine 1-Phosphate (SphK1/S1P) signaling pathway is overexpressed in various cancers, and is instrumental for the adaptation to hypoxia in a number of solid tumor models, but no data are available in osteosarcoma. Here we report that SphK1 and the S1P1 receptor are involved in HIF-1α accumulation in hypoxic osteosarcoma cells. FTY720 (Fingolimod), which targets SphK1 and S1P1, prevented HIF-1α accumulation, and also inhibited cell proliferation in both normoxia and hypoxia unlike conventional chemotherapy. In human biopsies, a significant increase of SphK1 activity was observed in cancer compared with normal bones. In all sets of TMA samples (130 cases of osteosarcoma), immunohistochemical analysis showed the hypoxic marker GLUT-1, SphK1 and S1P1 were expressed in tumors. SphK1 correlated with the GLUT-1 suggesting that SphK1 is overexpressed and correlates with intratumoral hypoxia. No correlation was found between GLUT-1 or SphK1 and response to chemotherapy, but a statistical difference was found with increased S1P1 expression in patients with poor response in long bone osteosarcomas. Importantly, multivariate analyses showed that GLUT-1 was associated with an increased risk of death in flat bone, whereas SphK1 and S1P1 were associated with an increased risk of death in long bones.
Collapse
Affiliation(s)
- Anne Gomez-Brouchet
- CNRS, Institut de Pharmacologie et de Biologie Structurale, 31077 Toulouse, France; (C.I.); (A.L.); (P.-Y.F.); (F.T.); (M.-L.M.)
- Université de Toulouse, UPS, 31400 Toulouse, France
- Département d’Anatomie et Cytologie Pathologies, Institut Universitaire du Cancer de Toulouse–Oncopôle (IUCT-O), 31059 Toulouse, France
- Cancer Biobank, Institut Universitaire du Cancer de Toulouse–Oncopôle (IUCT-O), 31059 Toulouse, France;
- Correspondence: (A.G.-B.); (O.C.)
| | - Claire Illac
- CNRS, Institut de Pharmacologie et de Biologie Structurale, 31077 Toulouse, France; (C.I.); (A.L.); (P.-Y.F.); (F.T.); (M.-L.M.)
- Université de Toulouse, UPS, 31400 Toulouse, France
- Département d’Anatomie et Cytologie Pathologies, Institut Universitaire du Cancer de Toulouse–Oncopôle (IUCT-O), 31059 Toulouse, France
| | - Adeline Ledoux
- CNRS, Institut de Pharmacologie et de Biologie Structurale, 31077 Toulouse, France; (C.I.); (A.L.); (P.-Y.F.); (F.T.); (M.-L.M.)
- Université de Toulouse, UPS, 31400 Toulouse, France
| | - Pierre-Yves Fortin
- CNRS, Institut de Pharmacologie et de Biologie Structurale, 31077 Toulouse, France; (C.I.); (A.L.); (P.-Y.F.); (F.T.); (M.-L.M.)
- Université de Toulouse, UPS, 31400 Toulouse, France
| | - Sandra de Barros
- Service de Pharmacologie Clinique, Hôpitaux de Toulouse, 31300 Toulouse, France; (S.d.B.); (C.V.); (F.D.); (S.P.)
| | - Clémentine Vabre
- Service de Pharmacologie Clinique, Hôpitaux de Toulouse, 31300 Toulouse, France; (S.d.B.); (C.V.); (F.D.); (S.P.)
| | - Fabien Despas
- Service de Pharmacologie Clinique, Hôpitaux de Toulouse, 31300 Toulouse, France; (S.d.B.); (C.V.); (F.D.); (S.P.)
| | - Sophie Peries
- Service de Pharmacologie Clinique, Hôpitaux de Toulouse, 31300 Toulouse, France; (S.d.B.); (C.V.); (F.D.); (S.P.)
| | - Christelle Casaroli
- Cancer Biobank, Institut Universitaire du Cancer de Toulouse–Oncopôle (IUCT-O), 31059 Toulouse, France;
| | - Corinne Bouvier
- Department of Pathology, CHU la Timone, 13005 Marseille, France;
| | | | | | - Frédérique Larousserie
- Department of Pathology, AP-HP, Hôpital Cochin, Universiteé Paris Descartes, 75014 Paris, France;
| | - Louise Galmiche
- Centre Hospitalier Universitaire de Nantes Hôtel Dieu, 44000 Nantes, France;
| | - Franck Talmont
- CNRS, Institut de Pharmacologie et de Biologie Structurale, 31077 Toulouse, France; (C.I.); (A.L.); (P.-Y.F.); (F.T.); (M.-L.M.)
- Université de Toulouse, UPS, 31400 Toulouse, France
| | - Stuart Pitson
- Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA 5000, Australia;
| | - Marie-Lise Maddelein
- CNRS, Institut de Pharmacologie et de Biologie Structurale, 31077 Toulouse, France; (C.I.); (A.L.); (P.-Y.F.); (F.T.); (M.-L.M.)
- Université de Toulouse, UPS, 31400 Toulouse, France
| | - Olivier Cuvillier
- CNRS, Institut de Pharmacologie et de Biologie Structurale, 31077 Toulouse, France; (C.I.); (A.L.); (P.-Y.F.); (F.T.); (M.-L.M.)
- Université de Toulouse, UPS, 31400 Toulouse, France
- Correspondence: (A.G.-B.); (O.C.)
| |
Collapse
|
10
|
Bouvier C, Souedet N, Levy J, Jan C, You Z, Herard AS, Mergoil G, Rodriguez BH, Clouchoux C, Delzescaux T. Reduced and stable feature sets selection with random forest for neurons segmentation in histological images of macaque brain. Sci Rep 2021; 11:22973. [PMID: 34836996 PMCID: PMC8626511 DOI: 10.1038/s41598-021-02344-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2020] [Accepted: 10/27/2021] [Indexed: 01/01/2023] Open
Abstract
In preclinical research, histology images are produced using powerful optical microscopes to digitize entire sections at cell scale. Quantification of stained tissue relies on machine learning driven segmentation. However, such methods require multiple additional information, or features, which are increasing the quantity of data to process. As a result, the quantity of features to deal with represents a drawback to process large series or massive histological images rapidly in a robust manner. Existing feature selection methods can reduce the amount of required information but the selected subsets lack reproducibility. We propose a novel methodology operating on high performance computing (HPC) infrastructures and aiming at finding small and stable sets of features for fast and robust segmentation of high-resolution histological images. This selection has two steps: (1) selection at features families scale (an intermediate pool of features, between spaces and individual features) and (2) feature selection performed on pre-selected features families. We show that the selected sets of features are stables for two different neuron staining. In order to test different configurations, one of these dataset is a mono-subject dataset and the other is a multi-subjects dataset to test different configurations. Furthermore, the feature selection results in a significant reduction of computation time and memory cost. This methodology will allow exhaustive histological studies at a high-resolution scale on HPC infrastructures for both preclinical and clinical research.
Collapse
Affiliation(s)
- C Bouvier
- CEA, CNRS, MIRCen, Laboratoire Des Maladies Neurodégénératives, Université Paris-Saclay, Fontenay-aux-Roses, France
- Witsee, Paris, France
| | - N Souedet
- CEA, CNRS, MIRCen, Laboratoire Des Maladies Neurodégénératives, Université Paris-Saclay, Fontenay-aux-Roses, France
| | - J Levy
- Service de Médecine Physique Et de Réadaptation - APHP Hôpital Raymond Poincaré, Garches, France
- UMR 1179, Handicap Neuromusculaire - INSERM-UVSQ, Montigny le Bretonneux, France
| | - C Jan
- CEA, CNRS, MIRCen, Laboratoire Des Maladies Neurodégénératives, Université Paris-Saclay, Fontenay-aux-Roses, France
| | - Z You
- CEA, CNRS, MIRCen, Laboratoire Des Maladies Neurodégénératives, Université Paris-Saclay, Fontenay-aux-Roses, France
- Shaanxi Key Laboratory for Network Computing and Security Technology, School of Computer Science and Engineering, Xi'an University of Technology, Xi'an, China
| | - A-S Herard
- CEA, CNRS, MIRCen, Laboratoire Des Maladies Neurodégénératives, Université Paris-Saclay, Fontenay-aux-Roses, France
| | | | | | - C Clouchoux
- CEA, CNRS, MIRCen, Laboratoire Des Maladies Neurodégénératives, Université Paris-Saclay, Fontenay-aux-Roses, France
- Witsee, Paris, France
| | - T Delzescaux
- CEA, CNRS, MIRCen, Laboratoire Des Maladies Neurodégénératives, Université Paris-Saclay, Fontenay-aux-Roses, France.
| |
Collapse
|
11
|
Apra C, Guillemot D, Frouin E, Bouvier C, Mokhtari K, Kalamarides M, Pierron G. Molecular description of meningeal solitary fibrous tumors/hemangiopericytomas compared to meningiomas: two completely separate entities. J Neurooncol 2021; 154:327-334. [PMID: 34417711 DOI: 10.1007/s11060-021-03830-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2021] [Accepted: 08/14/2021] [Indexed: 12/22/2022]
Abstract
INTRODUCTION Meningeal solitary fibrous tumors (SFT), like all SFT, are defined by NAB2-STAT6 fusion and share clinicopathologic similarities with meningiomas, the most frequent meningeal tumors. Our aim is to establish the molecular identity of meningeal SFT and seek molecular prognostic factors. METHODS RNA sequencing and whole exome sequencing were performed in STAT6-positive SFT and grade 2-3 meningiomas, and data concerning other soft tissues tumors was obtained from the local database. Uniform manifold approximation and projection, individual gene expression and Gene Set Enrichment Analysis were performed. RESULTS RNA clustering shows that SFT share a common molecular signature, different from any other type of tumoral tissue. Meningeal SFT aggregate with other SFT, with no clinical or histological subgroup. Comparison of genes expressions suggests significant over-expressions of ZIC2, ZIC3, ZIC5, GABBR2, TP53 in CNS-SFT. The pathogenic TP53 c.743G>T variant, previously undescribed in SFT, was found in one sample of meningeal SFT during malignant progression. CONCLUSIONS Meningeal SFT are molecular counterparts of extra-meningeal SFT, completely separate from meningiomas. They might develop from the same tissues and benefit from the same treatments as SFT.
Collapse
Affiliation(s)
- Caroline Apra
- Sorbonne Université, Paris, France.
- Department of Neurosurgery, Pitié-Salpêtrière Hospital, 47-83 bd de l'Hôpital, 75013, Paris, France.
- Paris Brain Institute, INSERM U1127, CNRS, UMR7225, 47-83 bd de l'Hôpital, 75013, Paris, France.
| | - Delphine Guillemot
- Pole of Diagnostic and Theranostic Medecine, Institut Curie, 26 rue d'Ulm, 75005, Paris, France
| | - Eléonore Frouin
- Pole of Diagnostic and Theranostic Medecine, Institut Curie, 26 rue d'Ulm, 75005, Paris, France
| | - Corinne Bouvier
- Department of Pathology, APHM, CHU Timone, INSERM, MMG Aix Marseille University, Marseille, France
| | - Karima Mokhtari
- Department of Neurosurgery, Pitié-Salpêtrière Hospital, 47-83 bd de l'Hôpital, 75013, Paris, France
- Paris Brain Institute, INSERM U1127, CNRS, UMR7225, 47-83 bd de l'Hôpital, 75013, Paris, France
- Department of Neuropathology, Pitié-Salpêtrière Hospital, 47-83 bd de l'Hôpital, 75013, Paris, France
| | - Michel Kalamarides
- Sorbonne Université, Paris, France
- Department of Neurosurgery, Pitié-Salpêtrière Hospital, 47-83 bd de l'Hôpital, 75013, Paris, France
- Paris Brain Institute, INSERM U1127, CNRS, UMR7225, 47-83 bd de l'Hôpital, 75013, Paris, France
| | - Gaëlle Pierron
- Pole of Diagnostic and Theranostic Medecine, Institut Curie, 26 rue d'Ulm, 75005, Paris, France
| |
Collapse
|
12
|
Blay JY, Casali P, Bouvier C, Dehais C, Galloway I, Gietema J, Halámková J, Hindi N, Idbaih A, Kinloch E, Klümpen HJ, Kolarova T, Kopeckova K, Lovey J, Magalhaes M, Oselin K, Piperno-Neumann S, Ravnsbaek A, Rogasik M, Safwat A, Scheipl S, Seckl M, Taylor J, Temnyk M, Trama A, Urbonas M, Wartenberg M, Weinman A. European Reference Network for rare adult solid cancers, statement and integration to health care systems of member states: a position paper of the ERN EURACAN. ESMO Open 2021; 6:100174. [PMID: 34139485 PMCID: PMC8219752 DOI: 10.1016/j.esmoop.2021.100174] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2021] [Revised: 05/12/2021] [Accepted: 05/13/2021] [Indexed: 11/04/2022] Open
Affiliation(s)
- J-Y Blay
- Department of Medical Oncology, Centre Leon Berard & Centre de Recherche en Cancérologie de Lyon (CRCL) & Université Claude Bernard Lyon 1, Lyon, France.
| | - P Casali
- Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy
| | - C Bouvier
- Neuroendocrine Cancer Unit, Royal Free Hospital, London, UK
| | - C Dehais
- Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, Paris, France
| | - I Galloway
- Melanoma Patient Network Europe, OcuMel, Birmingham, UK
| | - J Gietema
- Department of Medical Oncology, University Medical Centre Groningen, Groningen, The Netherlands
| | - J Halámková
- Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic
| | - N Hindi
- Institute of Biomedicine of Sevilla (IBIS, HUVR, CSIC, Universidad de Sevilla), Virgen, Virgen del Rocío University Hospital, Seville, Spain
| | - A Idbaih
- Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, Paris, France
| | | | - H-J Klümpen
- Department of Medical Oncology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
| | - T Kolarova
- International Neuroendocrine Cancer Alliance, Boston, USA
| | - K Kopeckova
- Department of Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
| | - J Lovey
- National Institute of Oncology, Budapest, Hungary
| | - M Magalhaes
- Oncology Department, Centro Hospitalar e Universitário Universitário do Porto, Porto, Portugal
| | - K Oselin
- Department of Chemotherapy, Clinic of Haematology and Oncology, North Estonia Medical Centre Foundation, Tallinn, Estonia
| | | | - A Ravnsbaek
- Oncology Department, and Danish Centre for Particle Therapy, University Hospital, Aarhus, Denmark
| | - M Rogasik
- Research and Innovation Department, Centre Léon Bérard, Lyon, France
| | - A Safwat
- Oncology Department, and Danish Centre for Particle Therapy, University Hospital, Aarhus, Denmark
| | - S Scheipl
- Medical University of Graz, Graz, Austria
| | - M Seckl
- Department of Medical Oncology, Charing Cross Hospital Campus of Imperial College London, London, UK
| | - J Taylor
- Thyroid Cancer Alliance, Rotterdam, The Netherlands
| | - M Temnyk
- Maria Skłodowska Curie Institute, Warsaw, Poland
| | - A Trama
- Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy
| | - M Urbonas
- Lithuanian University of Health Sciences, Department of Neurosurgery, Kaunas, Lithuania
| | | | - A Weinman
- EURORDIS-Rare Diseases Europe (European Patient Organisation for Rare Diseases)
| |
Collapse
|
13
|
Cyrta J, Gauthier A, Karanian M, Vieira AF, Cardoen L, Jehanno N, Bouvet M, Bouvier C, Komuta M, Le Loarer F, Orbach D, Rome A, Minard-Colin V, Brichard B, Pluchart C, Thebaud E, Renard M, Pannier S, Brisse H, Petit P, Benoist C, Schleiermacher G, Geoerger B, Vincent-Salomon A, Fréneaux P, Pierron G. Infantile Rhabdomyosarcomas With VGLL2 Rearrangement Are Not Always an Indolent Disease: A Study of 4 Aggressive Cases With Clinical, Pathologic, Molecular, and Radiologic Findings. Am J Surg Pathol 2021; 45:854-867. [PMID: 33949344 DOI: 10.1097/pas.0000000000001702] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
VGLL2-rearranged rhabdomyosarcomas (RMS) are rare low-grade tumors with only favorable outcomes reported to date. We describe 4 patients with VGLL2-rearranged RMS confirmed by molecular studies, who experienced local progression and distant metastases, including 2 with fatal outcomes. Tumors were diagnosed at birth (n=3) or at 12 months of age (n=1), and were all localized at initial diagnosis, but unresectable and therefore managed with chemotherapy and surveillance. Metastatic progression occurred from 1 to 8 years from diagnosis (median, 3.5 y). Three patients experienced multimetastatic spread and one showed an isolated adrenal metastasis. At initial diagnosis, 3 tumors displaying bland morphology were misdiagnosed as fibromatosis or infantile fibrosarcoma and initially managed as such, while 1 was a high-grade sarcoma. At relapse, 3 tumors showed high-grade morphology, while 1 retained a low-grade phenotype. Low-grade primary tumors showed only very focal positivity for desmin, myogenin, and/or MyoD1, while high-grade tumors were heterogenously or diffusely positive. Whole-exome sequencing, performed on primary and relapse samples for 3 patients, showed increased genomic instability and additional genomic alterations (eg, TP53, CDKN2A/B, FGFR4) at relapse, but no recurrent events. RNA sequencing confirmed that high-grade tumors retained VGLL2 fusion transcripts and transcriptomic profiles consistent with VGLL2-rearranged RMS. High-grade samples showed a high expression of genes encoding cell cycle proteins, desmin, and some developmental factors. These 4 cases with distinct medical history imply the importance of complete surgical resection, and suggest that RMS-type chemotherapy should be considered in unresectable cases, given the risk of high-grade transformation. They also emphasize the importance of correct initial diagnosis.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | - Mina Komuta
- Departments of Pathology
- Department of Pathology, School of Medicine, Keio University, Tokyo, Japan
| | | | - Daniel Orbach
- SIREDO Oncology Center (Care, Innovation and Research for Children and AYA With Cancer), Curie Institute, PSL Research University
| | | | - Véronique Minard-Colin
- Department of Pediatric and Adolescent Oncology, Gustave Roussy Cancer Campus, INSERM U1015, Paris-Saclay University, Villejuif
| | - Bénédicte Brichard
- Pediatric Hematology/Oncology, University Hospital Saint-Luc, Catholic University of Leuven, Brussels, Belgium
| | - Claire Pluchart
- Department of Paediatric Oncology/Hematology, American Hospital, University Hospital of Reims, Reims, France
| | - Estelle Thebaud
- Department of Pediatric Hemato-oncology, University Hospital of Nantes, Nantes
| | - Marleen Renard
- Pediatric Hematology/Oncology, University Hospital Saint-Luc, Catholic University of Leuven, Brussels, Belgium
| | - Stéphanie Pannier
- Department of Orthopedic Surgery, University Hospital Necker-Enfants-Malades, Paris
| | | | - Philippe Petit
- Radiology, La Timone Hospital, Aix Marseille University, Marseille
| | | | - Gudrun Schleiermacher
- SIREDO Oncology Center (Care, Innovation and Research for Children and AYA With Cancer), Curie Institute, PSL Research University
| | - Birgit Geoerger
- Department of Pediatric and Adolescent Oncology, Gustave Roussy Cancer Campus, INSERM U1015, Paris-Saclay University, Villejuif
| | | | | | | |
Collapse
|
14
|
Frankel D, Kaspi E, Bouvier C, Roll P. Pleural effusion in a patient with Ewing sarcoma. Cytopathology 2021; 33:138-140. [PMID: 34010486 DOI: 10.1111/cyt.12989] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2021] [Revised: 03/29/2021] [Accepted: 04/10/2021] [Indexed: 11/28/2022]
Affiliation(s)
- Diane Frankel
- Service de Biologie Cellulaire, AixMarseille Univ, APHM, INSERM, MMG, Hôpital la Timone, Marseille, France
| | - Elise Kaspi
- Service de Biologie Cellulaire, AixMarseille Univ, APHM, INSERM, MMG, Hôpital la Timone, Marseille, France
| | - Corinne Bouvier
- APHM, Hôpital la Timone Service d'anatomie Pathologique et de Neuropathologie, Marseille, France
| | - Patrice Roll
- Service de Biologie Cellulaire, AixMarseille Univ, APHM, INSERM, MMG, Hôpital la Timone, Marseille, France
| |
Collapse
|
15
|
Bouaoud J, Larousserie F, Galmiche-Rolland L, Bouvier C, Picard A, Khonsari RH. Protuberant fibro-osseous lesion of the temporal bone: report of four cases and review of the literature. Int J Oral Maxillofac Surg 2021; 50:1566-1570. [PMID: 33865660 DOI: 10.1016/j.ijom.2021.03.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2020] [Revised: 01/13/2021] [Accepted: 03/01/2021] [Indexed: 11/26/2022]
Abstract
'Bullough lesions', also referred to as protuberant fibro-osseous lesions (PFOL), are rare temporal bone lesions initially described in 1999. Since only 12 cases have been reported, several key issues, such as their origin and recommended management strategies, remain unresolved. This article reports the largest cohort included in the literature to date, comprising four patients with PFOL. PFOL appears to be characterized by female and right-side predominance. These lesions were consistently located regarding the mastoid, generally diagnosed in early adulthood, without functional symptoms, and were always fibro-osseous. Invasive/malignant features were not found on imaging or histology. The main differential diagnosis was malignant low-grade parosteal osteosarcoma. Clinical examination and computed tomography images provided strong elements supporting the diagnosis of PFOL. Biopsy allowed molecular biology investigations (MDM2 and CDK4 amplification), in order to rule out low-grade parosteal osteosarcoma.
Collapse
Affiliation(s)
- J Bouaoud
- Service de Chirurgie Maxillo-faciale et Chirurgie Plastique, Hôpital Necker - Enfants Malades, Assistance Publique - Hôpitaux de Paris, Université de Paris, Paris, France; Service de Chirurgie Maxillo-faciale et Stomatologie, Hôpital Pitié-Salpêtrière, Assistance Publique - Hôpitaux de Paris, Sorbonne Université, Paris, France.
| | - F Larousserie
- Service d'Anatomopathologie, Hôpital Cochin - Port-Royal, Assistance Publique - Hôpitaux de Paris, Université de Paris, Paris, France
| | - L Galmiche-Rolland
- Service d'Anatomopathologie, Hôpital Necker - Enfants Malades, Assistance Publique - Hôpitaux de Paris, Université de Paris, Paris, France
| | - C Bouvier
- Service d'Anatomopathologie, Hôpital La Timone, APHM, Marseille, France
| | - A Picard
- Service de Chirurgie Maxillo-faciale et Chirurgie Plastique, Hôpital Necker - Enfants Malades, Assistance Publique - Hôpitaux de Paris, Université de Paris, Paris, France
| | - R H Khonsari
- Service de Chirurgie Maxillo-faciale et Chirurgie Plastique, Hôpital Necker - Enfants Malades, Assistance Publique - Hôpitaux de Paris, Université de Paris, Paris, France
| |
Collapse
|
16
|
de Pinieux G, Karanian M, Le Loarer F, Le Guellec S, Chabaud S, Terrier P, Bouvier C, Batistella M, Neuville A, Robin YM, Emile JF, Moreau A, Larousserie F, Leroux A, Stock N, Lae M, Collin F, Weinbreck N, Aubert S, Mishellany F, Charon-Barra C, Croce S, Doucet L, Quintin-Rouet I, Chateau MC, Bazille C, Valo I, Chetaille B, Ortonne N, Brouchet A, Rochaix P, Demuret A, Ghnassia JP, Mescam L, Macagno N, Birtwisle-Peyrottes I, Delfour C, Angot E, Pommepuy I, Ranchere D, Chemin-Airiau C, Jean-Denis M, Fayet Y, Courrèges JB, Mesli N, Berchoud J, Toulmonde M, Italiano A, Le Cesne A, Penel N, Ducimetiere F, Gouin F, Coindre JM, Blay JY. Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network. PLoS One 2021; 16:e0246958. [PMID: 33630918 PMCID: PMC7906477 DOI: 10.1371/journal.pone.0246958] [Citation(s) in RCA: 116] [Impact Index Per Article: 38.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2020] [Accepted: 01/28/2021] [Indexed: 01/20/2023] Open
Abstract
BACKGROUND Since 2010, nationwide networks of reference centers for sarcomas (RREPS/NETSARC/RESOS) collected and prospectively reviewed all cases of sarcomas and connective tumors of intermediate malignancy (TIM) in France. METHODS The nationwide incidence of sarcoma or TIM (2013-2016) was measured using the 2013 WHO classification and confirmed by a second independent review by expert pathologists. Simple clinical characteristics, yearly variations and correlation of incidence with published clinical trials are presented and analyzed. RESULTS Over 150 different histological subtypes are reported from the 25172 patients with sarcomas (n = 18712, 74,3%) or TIM (n = 6460, 25.7%), with n = 5838, n = 6153, n = 6654, and n = 6527 yearly cases from 2013 to 2016. Over these 4 years, the yearly incidence of sarcomas and TIM was therefore 70.7 and 24.4 respectively, with a combined incidence of 95.1/106/year, higher than previously reported. GIST, liposarcoma, leiomyosarcomas, undifferentiated sarcomas represented 13%, 13%, 11% and 11% of tumors. Only GIST, as a single entity had a yearly incidence above 10/106/year. There were respectively 30, 64 and 66 different histological subtypes of sarcomas or TIM with an incidence ranging from 10 to 1/106, 1-0.1/106, or < 0.1/106/year respectively. The 2 latter incidence groups represented 21% of the patients with 130 histotypes. Published phase III and phase II clinical trials (p<10-6) are significantly higher with sarcomas subtypes with an incidence above 1/106 per. CONCLUSIONS This nationwide registry of sarcoma patients, with exhaustive histology review by sarcoma experts, shows that the incidence of sarcoma and TIM is higher than reported, and that tumors with a very low incidence (1<106/year) are less likely to be included in clinical trials.
Collapse
Affiliation(s)
| | - Marie Karanian
- Department of Biopathology, Centre Léon Bérard, Lyon, France
| | | | - Sophie Le Guellec
- Department of Biopathology, Institut Claudius Regaud et Institut Universitaire du Cancer de Toulouse—Oncopôle, Toulouse, France
| | - Sylvie Chabaud
- Department of Biopathology, Centre Léon Bérard, Lyon, France
| | | | - Corinne Bouvier
- Department of pathology, La Timone University Hospital, Marseille, France
| | - Maxime Batistella
- Pathology Department, Saint-Louis Hospital, AP-HP, Université de Paris, Paris, France
| | - Agnès Neuville
- Department of Biopathology, Institut Bergonié, Bordeaux, France
| | - Yves-Marie Robin
- Pôle de Biologie-Pathologie-Génétique Centre Oscar Lambret, & Institut de Pathologie entre Oscar Lambret & CHU Lille, Lille, France
| | | | - Anne Moreau
- Department of Pathology, Department of Orthopedy CHU Nantes, Nantes, France
| | | | - Agnes Leroux
- Department of Biopathology, Institut de Cancérologie de Lorraine—Alexis Vautrin, Vandoeuvre-lès-Nancy, France
| | - Nathalie Stock
- Department of Biopathology, Eugene Marquis Comprehensive Cancer Center & CHU Rennes, Rennes, France
| | - Marick Lae
- Department of Biopathology, Eugene Marquis Comprehensive Cancer Center & CHU Rennes, Rennes, France
- Department of Biopathology, Institut Curie, Paris, France
| | - Francoise Collin
- Department of Biopathology, Centre Georges François Leclerc, Dijon, France
| | | | - Sebastien Aubert
- Pôle de Biologie-Pathologie-Génétique Centre Oscar Lambret, & Institut de Pathologie entre Oscar Lambret & CHU Lille, Lille, France
| | | | | | - Sabrina Croce
- Department of Biopathology, Institut Bergonié, Bordeaux, France
| | | | | | - Marie-Christine Chateau
- Department of Biopathology, Institut de Cancérologie de Montpellier & CHU Montpellier, Montpellier, France
| | - Celine Bazille
- Department of Biopathology, Centre Francois Baclesse, Caen, France
| | - Isabelle Valo
- Department of Pathology, Institut de Cancerologie de l’Ouest, Angers, France
| | | | - Nicolas Ortonne
- Department of Biopathology, Hopital Henri Mondor, Creteil, France
| | - Anne Brouchet
- Department of Biopathology, Institut Claudius Regaud et Institut Universitaire du Cancer de Toulouse—Oncopôle, Toulouse, France
| | - Philippe Rochaix
- Department of Biopathology, Institut Claudius Regaud et Institut Universitaire du Cancer de Toulouse—Oncopôle, Toulouse, France
| | - Anne Demuret
- Department of pathology, CHU de Tours, Tours, France
| | | | - Lenaig Mescam
- Department of Biopathology, Institut Paoli Calmettes, Marseille, France
| | - Nicolas Macagno
- Department of pathology, La Timone University Hospital, Marseille, France
| | | | - Christophe Delfour
- Department of Biopathology, Institut de Cancérologie de Montpellier & CHU Montpellier, Montpellier, France
| | - Emilie Angot
- Department of Biopathology, Eugene Marquis Comprehensive Cancer Center & CHU Rennes, Rennes, France
| | | | | | | | | | - Yohan Fayet
- Department of Biopathology, Centre Léon Bérard, Lyon, France
| | | | - Nouria Mesli
- Department of Biopathology, Institut Bergonié, Bordeaux, France
| | - Juliane Berchoud
- Department of Pathology, Department of Orthopedy CHU Nantes, Nantes, France
| | - Maud Toulmonde
- Department of Biopathology, Institut Bergonié, Bordeaux, France
| | | | - Axel Le Cesne
- Department of Biopathology, Centre Léon Bérard, Lyon, France
| | - Nicolas Penel
- Pôle de Biologie-Pathologie-Génétique Centre Oscar Lambret, & Institut de Pathologie entre Oscar Lambret & CHU Lille, Lille, France
| | | | - Francois Gouin
- Department of Biopathology, Centre Léon Bérard, Lyon, France
| | | | - Jean-Yves Blay
- Department of Biopathology, Centre Léon Bérard, Lyon, France
- Department of Medicine of Centre Leon Berard, University Claude Bernard Lyon I, Lyon, France
- Headquarters, Unicancer, Paris, France
- * E-mail:
| | | |
Collapse
|
17
|
Barets D, Appay R, Heinisch M, Battistella M, Bouvier C, Chotard G, Le Loarer F, Macagno N, Perbet R, Pissaloux D, Rousseau A, Tauziède-Espariat A, Varlet P, Vasiljevic A, Colin C, Fina F, Figarella-Branger D. Specific and Sensitive Diagnosis of BCOR-ITD in Various Cancers by Digital PCR. Front Oncol 2021; 11:645512. [PMID: 33718245 PMCID: PMC7948083 DOI: 10.3389/fonc.2021.645512] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2020] [Accepted: 01/27/2021] [Indexed: 11/25/2022] Open
Abstract
BCOR is an epigenetic regulator altered by various mechanisms including BCOR-internal tandem duplication (BCOR-ITD) in a wide range of cancers. Six different BCOR-ITD in the 3’-part of the coding sequence of exon 15 have been reported ranging from 89 to 114 bp in length. BCOR-ITD is a common genetic alteration found in clear cell sarcoma of the kidney and primitive myxoid mesenchymal tumor of infancy (PMMTI) and it characterizes a new type of central nervous system tumor: “CNS tumor with BCOR-ITD”. It can also be detected in undifferentiated round cell sarcoma (URCS) and in high-grade endometrial stromal sarcoma (HGESS). Therefore, it is of utmost importance to search for this genetic alteration in these cancers with the most frequent technique being RNA-sequencing. Here, we developed a new droplet PCR assay (dPCR) to detect the six sequences characterizing BCOR-ITD. To achieve this goal, we used a single colored probe to detect both the duplicated region and the normal sequence that acts as a reference. We first generated seven synthetic DNA sequences: ITD0 (the normal sequence) and ITD1 to ITD6 (the duplicated sequences described in the literature) and then we set up the optima dPCR conditions. We validated our assay on 19 samples from a representative panel of human tumors (9 HGNET-BCOR, 5 URCS, 3 HGESS, and 2 PMMTI) in which BCOR-ITD status was known using at least one other method including RNA sequencing, RT-PCR or DNA-methylation profiling for CNS tumors. Our results showed that our technique was 100% sensitive and specific. DPCR detected BCOR-ITD in 13/19 of the cases; in the remaining 6 cases additional RNA-sequencing revealed BCOR gene fusions. To conclude, in the era of histomolecular classification of human tumors, our modified dPCR assay is of particular interest to detect BCOR-ITD since it is a robust and less expensive test that can be applied to a broad spectrum of cancers that share this alteration.
Collapse
Affiliation(s)
- Doriane Barets
- APHM, CHU Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France
| | - Romain Appay
- APHM, CHU Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France.,Aix-Marseille Univ, CNRS, INP, Inst Neurophysiopathol, Marseille, France
| | - Marie Heinisch
- APHM, CHU Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France
| | - Maxime Battistella
- Department of Pathology, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Université de Paris, Inserm U976, Paris, France
| | - Corinne Bouvier
- APHM, CHU Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France
| | - Guillaume Chotard
- Service de Pathologie, Groupe Hospitalier Pellegrin, CHU de Bordeaux, Bordeaux, France
| | | | - Nicolas Macagno
- APHM, CHU Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France
| | - Romain Perbet
- Institute of Pathology, CHU Lille, Lille, France.,LilNCog, Lille Neuroscience and Cognition, Univ. Lille, Inserm, CHU Lille, U1172, Lille, France
| | - Daniel Pissaloux
- Department of Translational Research and Innovation, Léon Bérard Cancer Center, Lyon, France.,Claude Bernard University Lyon 1, INSERM 1052, CNRS 5286, Cancer Research Center of Lyon, Centre Léon Bérard, Lyon, France
| | - Audrey Rousseau
- Département de Pathologie Cellulaire et Tissulaire, CHU Angers, Angers, France
| | - Arnaud Tauziède-Espariat
- Department of Neuropathology, GHU Paris-Psychiatrie Et Neurosciences, Sainte-Anne Hospital, Paris, France
| | - Pascale Varlet
- Department of Neuropathology, GHU Paris-Psychiatrie Et Neurosciences, Sainte-Anne Hospital, Paris, France
| | - Alexandre Vasiljevic
- Centre de Pathologie Est, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, France
| | - Carole Colin
- Aix-Marseille Univ, CNRS, INP, Inst Neurophysiopathol, Marseille, France
| | - Frédéric Fina
- APHM, CHU Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France.,ID Solutions, Research and Development, Grabels, France
| | - Dominique Figarella-Branger
- APHM, CHU Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France.,Aix-Marseille Univ, CNRS, INP, Inst Neurophysiopathol, Marseille, France
| |
Collapse
|
18
|
Legrand M, Jourdan ML, Tallet A, Collin C, Audard V, Larousserie F, Aubert S, Gomez-Brouchet A, Bouvier C, de Pinieux G. Novel partners of USP6 gene in a spectrum of bone and soft tissue lesions. Virchows Arch 2021; 479:147-156. [PMID: 33558945 DOI: 10.1007/s00428-021-03047-z] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2020] [Revised: 01/10/2021] [Accepted: 01/28/2021] [Indexed: 12/16/2022]
Abstract
Nodular fasciitis, primary aneurysmal bone cyst, myositis ossificans, and their related lesions are benign tumors that share common histological features and a chromosomal rearrangement involving the ubiquitin-specific peptidase 6 (USP6) gene. The identification of an increasing number of new partners implicated in USP6 rearrangements demonstrates a complex tumorogenesis of this tumor spectrum. In this study on a series of 77 tumors (28 nodular fasciitis, 42 aneurysmal bone cysts, and 7 myositis ossificans) from the database of the French Sarcoma Group, we describe 7 new partners of the USP6 gene. For this purpose, rearrangements were first researched by multiplexed RT-qPCRs in the entire population. A targeted RNA sequencing was then used on samples selected according to a high USP6-transcription level expression estimated by RT-qPCR. Thanks to this multistep approach, besides the common USP6 fusions observed, we detected novel USP6 partners: PDLIM7 and MYL12A in nodular fasciitis and TPM4, DDX17, GTF2I, KLF3, and MEF2A in aneurysmal bone cysts. In order to try to bring to light the role played by the recently identified USP6 partners in this lesional spectrum, their functions are discussed. Taking into account that a traumatic participation has long been mentioned in the histogenesis of most of these lesions and because of their morphological resemblance to organizing granulation reparative tissue or callus, a focus is placed on their relationship with tissue remodeling and, to a lesser extent, with bone metabolism.
Collapse
Affiliation(s)
- Mélanie Legrand
- Service d'anatomie et cytologie pathologiques, CHRU de Tours, Avenue de la République, 37044 Cedex 9, Tours, France
| | - Marie-Lise Jourdan
- Plateforme de Génétique moléculaire des cancers, CHRU de Tours, Tours, France
| | - Anne Tallet
- Plateforme de Génétique moléculaire des cancers, CHRU de Tours, Tours, France
| | - Christine Collin
- Plateforme de Génétique moléculaire des cancers, CHRU de Tours, Tours, France
| | - Virginie Audard
- Service d'anatomie et cytologie pathologiques, Hôpital Cochin, Paris, France
| | | | - Sébastien Aubert
- Service d'anatomie et cytologie pathologiques, CHU de Lille, Lille, France
| | | | - Corinne Bouvier
- Service d'anatomie et cytologie pathologiques, CHU de Marseille La Timone, Marseille, France
| | - Gonzague de Pinieux
- Service d'anatomie et cytologie pathologiques, CHRU de Tours, Avenue de la République, 37044 Cedex 9, Tours, France. .,PRES Centre-Val de Loire Université, Université François-Rabelais de Tours, Tours, France.
| |
Collapse
|
19
|
Habre C, Dabadie A, Loundou AD, Banos JB, Desvignes C, Pico H, Aschero A, Colavolpe N, Seiler C, Bouvier C, Peltier E, Gentet JC, Baunin C, Auquier P, Petit P. Diffusion-weighted imaging in differentiating mid-course responders to chemotherapy for long-bone osteosarcoma compared to the histologic response: an update. Pediatr Radiol 2021; 51:1714-1723. [PMID: 33877417 PMCID: PMC8363524 DOI: 10.1007/s00247-021-05037-4] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/24/2020] [Revised: 10/28/2020] [Accepted: 02/28/2021] [Indexed: 11/10/2022]
Abstract
BACKGROUND Diffusion-weighted imaging (DWI) has been described to correlate with tumoural necrosis in response to preoperative chemotherapy for osteosarcoma. OBJECTIVE To assess the accuracy of DWI in evaluating the response to neoadjuvant chemotherapy at the mid-course treatment of long-bone osteosarcoma and in predicting survival. MATERIALS AND METHODS We conducted a prospective single-centre study over a continuous period of 11 years. Consecutive patients younger than 20 years treated with a neoadjuvant regimen for peripheral conventional osteosarcoma were eligible for inclusion. Magnetic resonance imaging (MRI) with DWI was performed at diagnosis, and mid- and end-course chemotherapy with mean apparent diffusion coefficients (ADC) calculated at each time point. A percentage less than or equal to 10% of the viable residual tissue at the histological analysis of the surgical specimen was defined as a good responder to chemotherapy. Survival comparisons were calculated using the Kaplan-Meier method. Uni- and multivariate analyses with ADC change were performed by Cox modelling. This is an expansion and update of our previous work. RESULTS Twenty-six patients between the ages of 4.8 and 19.6 years were included, of whom 14 were good responders. At mid-course chemotherapy, good responders had significantly higher mean ADC values (P=0.046) and a higher increase in ADC (P=0.015) than poor responders. The ADC change from diagnosis to mid-course MRI did not appear to be a prognosticator of survival and did not impact survival rates of both groups. CONCLUSION DWI at mid-course preoperative chemotherapy for osteosarcoma should be considered to evaluate the degree of histological necrosis and to predict survival. The anticipation of a response to neoadjuvant treatment by DWI may have potential implications on preoperative management.
Collapse
Affiliation(s)
- Céline Habre
- Division of Pediatric Radiology, Hôpital Timone Enfants, Assistance publique - Hôpitaux de Marseille, 264 Rue Sainte Pierre, 13385, Marseille Cedex 05, France. .,Division of Pediatric Onco-Hematology, Hôpitaux Universitaires de Genève, Genève, Suisse.
| | - Alexia Dabadie
- grid.414336.70000 0001 0407 1584Division of Pediatric Radiology, Hôpital Timone Enfants, Assistance publique - Hôpitaux de Marseille, 264 Rue Sainte Pierre, 13385 Marseille Cedex 05, France
| | - Anderson D. Loundou
- grid.5399.60000 0001 2176 4817Division of Statistics and Methodology for Clinical Research, Assistance publique - Hôpitaux de Marseille, Aix-Marseille Université, Marseille, France
| | - Jean-Bruno Banos
- grid.414336.70000 0001 0407 1584Division of Pediatric Radiology, Hôpital Timone Enfants, Assistance publique - Hôpitaux de Marseille, 264 Rue Sainte Pierre, 13385 Marseille Cedex 05, France
| | - Catherine Desvignes
- grid.414336.70000 0001 0407 1584Division of Pediatric Radiology, Hôpital Timone Enfants, Assistance publique - Hôpitaux de Marseille, 264 Rue Sainte Pierre, 13385 Marseille Cedex 05, France
| | - Harmony Pico
- grid.414336.70000 0001 0407 1584Division of Pediatric Radiology, Hôpital Timone Enfants, Assistance publique - Hôpitaux de Marseille, 264 Rue Sainte Pierre, 13385 Marseille Cedex 05, France
| | - Audrey Aschero
- grid.414336.70000 0001 0407 1584Division of Pediatric Radiology, Hôpital Timone Enfants, Assistance publique - Hôpitaux de Marseille, 264 Rue Sainte Pierre, 13385 Marseille Cedex 05, France
| | - Nathalie Colavolpe
- grid.414336.70000 0001 0407 1584Division of Pediatric Radiology, Hôpital Timone Enfants, Assistance publique - Hôpitaux de Marseille, 264 Rue Sainte Pierre, 13385 Marseille Cedex 05, France
| | - Charlotte Seiler
- grid.414336.70000 0001 0407 1584Division of Pediatric Radiology, Hôpital Timone Enfants, Assistance publique - Hôpitaux de Marseille, 264 Rue Sainte Pierre, 13385 Marseille Cedex 05, France
| | - Corinne Bouvier
- grid.414336.70000 0001 0407 1584Anatomopathology Laboratory, Hôpital Timone Enfants, Assistance publique - Hôpitaux de Marseille, Marseille, France
| | - Emilie Peltier
- grid.414336.70000 0001 0407 1584Division of Pediatric Radiology and Prenatal Imaging, Hôpital Timone Enfants, Assistance publique - Hôpitaux de Marseille, Marseille, France
| | - Jean-Claude Gentet
- grid.414336.70000 0001 0407 1584Division of Pediatric Orthopedic Surgery, Hôpital Timone Enfants, Assistance publique - Hôpitaux de Marseille, Marseille, France
| | - Christiane Baunin
- grid.414336.70000 0001 0407 1584Division of Pediatric Radiology, Hôpital Timone Enfants, Assistance publique - Hôpitaux de Marseille, 264 Rue Sainte Pierre, 13385 Marseille Cedex 05, France
| | - Pascal Auquier
- grid.5399.60000 0001 2176 4817Division of Statistics and Methodology for Clinical Research, Assistance publique - Hôpitaux de Marseille, Aix-Marseille Université, Marseille, France
| | - Philippe Petit
- grid.414336.70000 0001 0407 1584Division of Pediatric Radiology, Hôpital Timone Enfants, Assistance publique - Hôpitaux de Marseille, 264 Rue Sainte Pierre, 13385 Marseille Cedex 05, France ,grid.5399.60000 0001 2176 4817Division of Statistics and Methodology for Clinical Research, Assistance publique - Hôpitaux de Marseille, Aix-Marseille Université, Marseille, France
| |
Collapse
|
20
|
Delteil C, Haffner A, Fritih R, Bouvier C, Taix S, Macagno N. [Point of view: A lesson from lockdown, histopathology through videoconferencing]. Ann Pathol 2020; 41:4-8. [PMID: 33039153 PMCID: PMC7539803 DOI: 10.1016/j.annpat.2020.09.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2020] [Revised: 08/25/2020] [Accepted: 09/18/2020] [Indexed: 11/29/2022]
Abstract
Le confinement et la distanciation sociale ont généralisé l’usage de la visioconférence, tant dans la sphère privée que professionnelle. Ainsi, l’utilisation de la visioconférence a considérablement augmenté durant la période du confinement et cette technologie a été utilisée dans le service d’anatomie pathologique du centre hospitalo-universitaire Timone, à Marseille, à visée universitaire, hospitalière et de recours. Nous apportons notre point de vue concernant l’utilisation de cet outil informatique. La discussion de lames par visioconférence est un exercice nouveau et particulier ; plusieurs recommandations sont émises pour un bon déroulement de ces réunions d’histopathologie à distance.
Collapse
Affiliation(s)
- Clémence Delteil
- Anatomie pathologique, AP-HM, CHU de Timone, Marseille, France; Institut médico-légal de Marseille, AP-HM, CHU de Timone, 264, rue St-Pierre, 13385 Marseille, France.
| | - Aurélie Haffner
- Anatomie pathologique, AP-HM, CHU de Timone, Marseille, France
| | - Radia Fritih
- Anatomie pathologique, AP-HM, CHU de Timone, Marseille, France
| | - Corinne Bouvier
- Anatomie pathologique, AP-HM, CHU de Timone, Marseille, France; Aix-Marseille Université, Inserm, MMG, Marseille, France
| | - Sébastien Taix
- Biopathologie, institut Paoli-Calmettes, Marseille, France
| | - Nicolas Macagno
- Anatomie pathologique, AP-HM, CHU de Timone, Marseille, France; Aix-Marseille Université, Inserm, MMG, Marseille, France
| |
Collapse
|
21
|
Duffaud F, Blay JY, Mir O, Chevreau C, Rouquette PB, Kalbacher E, Penel N, Perrin C, Laurence V, Bompas E, Saada-Bouzid E, Delcambre C, Bertucci F, Cancel M, Schiffler C, Monard L, Bouvier C, Vidal V, Gaspar N, Chabaud S. LBA68 Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REG) in patients (pts) with metastatic relapsed Ewing sarcoma (ES), on behalf of the French Sarcoma Group (FSG) and UNICANCER. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.2309] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
22
|
Miquelestorena-Standley E, Jourdan ML, Collin C, Bouvier C, Larousserie F, Aubert S, Gomez-Brouchet A, Guinebretière JM, Tallegas M, Brulin B, Le Nail LR, Tallet A, Le Loarer F, Massiere J, Galant C, de Pinieux G. Effect of decalcification protocols on immunohistochemistry and molecular analyses of bone samples. Mod Pathol 2020; 33:1505-1517. [PMID: 32094425 DOI: 10.1038/s41379-020-0503-6] [Citation(s) in RCA: 38] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2019] [Revised: 02/06/2020] [Accepted: 02/06/2020] [Indexed: 01/08/2023]
Abstract
Diagnosis of osteocartilaginous pathologies depends on morphological examination and immunohistochemical and molecular biology analyses. Decalcification is required before tissue processing, but available protocols often lead to altered proteins and nucleic acids, and thus compromise the diagnosis. The objective of this study was to compare the effect of different methods of decalcification on histomolecular analyses required for diagnosis and to recommend an optimal protocol for processing these samples in routine practice. We prospectively submitted 35 tissue samples to different decalcification procedures with hydrochloric acid, formic acid, and EDTA, in short, overnight and long cycles for 1 to >10 cycles. Preservation of protein integrity was examined by immunohistochemistry, and quality of nucleic acids was estimated after extraction (DNA and RNA concentrations, 260/280 ratios, PCR cycle thresholds), analysis of DNA mutations (high-resolution melting) or amplifications (PCR, in situ hybridization), and detection of fusion transcripts (RT-PCR, in situ hybridization). Hydrochloric acid- and long-term formic acid-based decalcification induced false-negative results on immunohistochemistry and molecular analysis. EDTA and short-term formic acid-based decalcification (<5 cycles of 6 h each) did not alter antigenicity and allowed for detection of gene mutations, amplifications or even fusion transcripts. EDTA showed superiority for in situ hybridization techniques. According to these results and our institutional experience, we propose recommendations for decalcification of bone samples, from biopsies to surgical specimens.
Collapse
Affiliation(s)
- Elodie Miquelestorena-Standley
- CHRU de Tours, Service d'anatomie et cytologie pathologiques, Tours, France. .,Université de Tours, PRES Centre-Val de Loire Université, Tours, France.
| | - Marie-Lise Jourdan
- CHRU de Tours, Plateforme de Génétique Moléculaire des Cancers, Tours, France
| | - Christine Collin
- CHRU de Tours, Plateforme de Génétique Moléculaire des Cancers, Tours, France
| | - Corinne Bouvier
- CHU de Marseille La Timone, Laboratoire d'anatomie et cytologie pathologiques, Marseille, France
| | | | - Sébastien Aubert
- CHU de Lille, Laboratoire d'anatomie et cytologie pathologiques, Lille, France
| | | | | | - Matthias Tallegas
- CHRU de Tours, Service d'anatomie et cytologie pathologiques, Tours, France.,Université de Tours, PRES Centre-Val de Loire Université, Tours, France
| | - Bénédicte Brulin
- INSERM UMR 1238, Laboratoire d'étude des sarcomes osseux et remodelage des tissus calcifiés, Nantes, France
| | - Louis-Romée Le Nail
- Université de Tours, PRES Centre-Val de Loire Université, Tours, France.,INSERM UMR 1238, Laboratoire d'étude des sarcomes osseux et remodelage des tissus calcifiés, Nantes, France.,CHRU de Tours, Service de chirurgie orthopédique, Tours, France
| | - Anne Tallet
- CHRU de Tours, Plateforme de Génétique Moléculaire des Cancers, Tours, France
| | | | - Jessica Massiere
- Institut Bergonié, Service d'anatomie pathologique, Bordeaux, France
| | - Christine Galant
- Cliniques Universitaires Saint-Luc, Laboratoire d'anatomie et cytologie pathologiques, Bruxelles, Belgique
| | - Gonzague de Pinieux
- CHRU de Tours, Service d'anatomie et cytologie pathologiques, Tours, France.,Université de Tours, PRES Centre-Val de Loire Université, Tours, France.,INSERM UMR 1238, Laboratoire d'étude des sarcomes osseux et remodelage des tissus calcifiés, Nantes, France
| |
Collapse
|
23
|
Di Mauro I, Mescam-Mancini L, Chetaille B, Lae M, Pierron G, Dadone-Montaudie B, Bazin A, Bouvier C, Michiels JF, Pedeutour F. MDM2 amplification and fusion gene ss18-ssx in a poorly differentiated synovial sarcoma: A rare but puzzling conjunction. Neoplasia 2020; 22:311-321. [PMID: 32559641 PMCID: PMC7303914 DOI: 10.1016/j.neo.2020.05.003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2019] [Revised: 04/30/2020] [Accepted: 05/17/2020] [Indexed: 01/30/2023]
Abstract
The detection of specific alterations by genetic analyses has been included in the diagnostic criterions of the World Health Organization's classification of soft tissues tumors since 2013. The presence of a SS18 rearrangement is pathognomonic of synovial sarcoma (SS). MDM2 amplification is strongly correlated to well-differentiated or dedifferentiated liposarcoma (DDLPS) in the context of sarcoma. We identified one case of poorly differentiated sarcoma harboring both SS18-SSX2 fusion and MDM2 amplification. The review of the literature showed high discrepancies, concerning the incidence of MDM2 amplification in SS: from 1.4% up to 40%. Our goal was to precisely determine the specific clinico-pathological features of this case and to estimate the frequency and characteristics of the association of SS18-SSX fusion/MDM2 amplification in sarcomas. We performed a retrospective and prospective study in 96 sarcomas, (56 SS and 40 DDLPS), using FISH and/or array-CGH to detect MDM2 amplification and SS18 rearrangement. None of the 96 cases presented both genetic alterations. Among the SS, only the index case (1/57: 1.7 %) presented the double anomaly. We concluded that MDM2 amplification in SS is a very rare event. The final diagnosis of the index case was a SS with SS18-SSX2 and MDM2 amplification as a secondary alteration. If the detection of MDM2 amplification is performed first in a poorly differentiated sarcoma, that may lead to not search other anomalies such as SS18 rearrangement and therefore to an erroneous diagnosis. This observation emphasizes the strong complementarity between histomorphology, immunohistochemistry and molecular studies in sarcoma diagnosis.
Collapse
Affiliation(s)
- Ilaria Di Mauro
- Laboratory of Solid Tumor Genetics, University Hospital of Nice-Côte d'Azur University, Nice, France; Laboratory of Solid Tumor Genetics, Institute for Research on Cancer and Aging of Nice (IRCAN), CNRS UMR 7284/INSERM U1081, Nice, France
| | | | - Bruno Chetaille
- Department of Cancer Biology, Paoli-Calmettes Institute, Marseille, France
| | - Marick Lae
- Department of Pathology, Curie Institute, Paris, France; Department of Pathology, Henri Becquerel Center, INSERM U1245, UniRouen Normandie University, Rouen, France
| | | | - Bérengère Dadone-Montaudie
- Laboratory of Solid Tumor Genetics, University Hospital of Nice-Côte d'Azur University, Nice, France; Laboratory of Solid Tumor Genetics, Institute for Research on Cancer and Aging of Nice (IRCAN), CNRS UMR 7284/INSERM U1081, Nice, France; Central Laboratory of Pathology, University Hospital of Nice-Côte d'Azur University, Nice, France
| | - Audrey Bazin
- Laboratory of Solid Tumor Genetics, University Hospital of Nice-Côte d'Azur University, Nice, France; Laboratory of Solid Tumor Genetics, Institute for Research on Cancer and Aging of Nice (IRCAN), CNRS UMR 7284/INSERM U1081, Nice, France
| | - Corinne Bouvier
- Department of Pathology, Timone Hospital, APHM, Marseille, France
| | - Jean-François Michiels
- Central Laboratory of Pathology, University Hospital of Nice-Côte d'Azur University, Nice, France
| | - Florence Pedeutour
- Laboratory of Solid Tumor Genetics, University Hospital of Nice-Côte d'Azur University, Nice, France; Laboratory of Solid Tumor Genetics, Institute for Research on Cancer and Aging of Nice (IRCAN), CNRS UMR 7284/INSERM U1081, Nice, France.
| |
Collapse
|
24
|
Nihous H, Macagno N, Baud-Massière J, Haffner A, Jouve JL, Gentet JC, Touzery C, Le Loarer F, Bouvier C. Genetic variant of SRF-rearranged myofibroma with a misleading nuclear expression of STAT6 and STAT6 involvement as 3' fusion partner. Virchows Arch 2020; 478:597-603. [PMID: 32529351 DOI: 10.1007/s00428-020-02859-9] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2019] [Revised: 05/04/2020] [Accepted: 05/28/2020] [Indexed: 11/28/2022]
Abstract
Pediatric neoplasms with a myofibroblastic differentiation are frequent in children, in particular myofibroma. Recently, a novel deep soft tissue myofibroblastic neoplasm has been described with high cellularity, a smooth muscle phenotype and SRF-RELA fusion. We report the case of a 15-year-old boy who presented with a tumor of the deep soft tissue of the arm, with overlapping histological features with the recently described SRF-RELA group of myofibromas but differing by the presence of calcifications, a novel SRF-STAT6 fusion transcript and nuclear expression of STAT6. No local recurrence nor distant metastasis was detected at the current follow-up of 29 months. The clinical relevance of this novel fusion requires further investigations.
Collapse
Affiliation(s)
- Hugo Nihous
- Department of Pathology, INSERM, MMG, APHM, CHU Timone, Aix Marseille University, Marseille, France
| | - Nicolas Macagno
- Department of Pathology, INSERM, MMG, APHM, CHU Timone, Aix Marseille University, Marseille, France
| | | | - Aurélie Haffner
- Department of Pathology, INSERM, MMG, APHM, CHU Timone, Aix Marseille University, Marseille, France
| | - Jean-Luc Jouve
- Department of Pediatric orthopedic, APHM, La Timone Children's Hospital, Marseille, France
| | - Jean-Claude Gentet
- Department of Pediatric Hematology and Oncology, APHM, La Timone Children's Hospital, Marseille, France
| | - Camille Touzery
- Department of Radiology, APHM, Hopital Nord, Marseille, France
| | | | - Corinne Bouvier
- Department of Pathology, INSERM, MMG, APHM, CHU Timone, Aix Marseille University, Marseille, France. .,Service d'Anatomie & Cytologie Pathologiques, Neuropathologie, CHU Timone, Rue Saint-Pierre, 13005, Marseille, France.
| |
Collapse
|
25
|
De Pinieux G, Karanian M, Le Loarer F, Le Guellec S, Terrier P, Bouvier C, Battistella M, Robin YM, Emile JF, Moreau A, Larousserie F, Leroux A, Stock N, Laé M, Collin F, Italiano A, Le Cesne A, Penel N, Coindre JM, Blay JY. Nationwide incidence of sarcomas and tumors of intermediate malignancy in the NETSARC network with central pathology review: Correlation with published clinical research. J Clin Oncol 2020. [DOI: 10.1200/jco.2020.38.15_suppl.11560] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
11560 Background: Since 2010, presentation to a designated sarcoma tumor board and pathological review by an expert network are mandatory for sarcoma patients in France. NETSARC+ (merging the 3 initial RREPS, RESOS & NETSARC) collected prospectively all cases of reviewed sarcomas and tumors of intermediate malignancy (TIM) nationwide. We report on the incidence of subtypes according to WHO classification from 2013 to 2016. Methods: Sarcoma expert pathologists reviewed samples were all prospectively integrated in the database; the results using the latest WHO classification are presented for the years 2013 to 2016, including yearly variations. Correlation of the incidence of each histotype with dedicated published clinical trials was conducted. Results: 139 different histological subtypes are reported among the 25172 patients with sarcomas (n = 18710, 64%) or TIM (n = 6460, 36%), respectively n = 5838, n = 6153, n = 6654, and n = 6527 yearly from 2013 to 2016. Over these 4 years, the observed yearly incidence of sarcomas, TIM, and all was therefore 79.7, 24.9 and 95.1/10e6/year, above that previously reported. GIST, liposarcoma, leiomyosarcomas, undifferentiated sarcomas represented 13%, 13%, 11% and 11% of all sarcomas. Only GIST, as a single entity exceeded a yearly incidence above 10/million per year. There were respectively 30, 63 and 66 different histological subtypes of sarcomas or TIM (single entities or lumped together, e.g. MPNST, or vascular sarcomas...) with an incidence ranging from 10 to 1/10e6/year, 1-0.1/10e6 per year, or < 0.1/10e6/year respectively. The 2 later “incidence groups” included 21% of the patients. The incidence of 8 histotypes varied significantly over this 4 years. Patients with tumors with an incidence above 1/10e6 per year have significantly higher numbers of dedicated published phase III and phase II clinical trials (p < 10e-6). Conclusions: This nationwide registry of sarcoma patients with an histology reviewed by sarcoma experts shows that the incidence of sarcoma and TIM is higher than previously reported, may vary over years for some histotypes, and that tumors with an incidence < 10e6 have a much lower access to clinical trials.
Collapse
Affiliation(s)
| | - Marie Karanian
- Department of Pathology, Centre Leon Bérard, Lyon, France
| | | | | | | | - Corinne Bouvier
- Assistance Publique-Hopitaux De Marseille, Marseille, France
| | | | | | - Jean-François Emile
- Ambroise Paré Hospital, Versailles University, Boulogne, France, Boulogne, France
| | | | | | - Agnès Leroux
- Centre Alexis Vautrin, Pathology and Tumor Biology Dept, EA4421 SiGReTO Nancy University, Vandoeuvre-Lès-Nancy, France
| | | | | | | | | | | | - Nicolas Penel
- Department of Medical Oncology, Centre Oscar Lambret, Lille, France
| | | | | | | |
Collapse
|
26
|
Chiarello M, Auguet JC, Graham NAJ, Claverie T, Sucré E, Bouvier C, Rieuvilleneuve F, Restrepo-Ortiz CX, Bettarel Y, Villéger S, Bouvier T. Exceptional but vulnerable microbial diversity in coral reef animal surface microbiomes. Proc Biol Sci 2020; 287:20200642. [PMID: 32396801 DOI: 10.1098/rspb.2020.0642] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
Coral reefs host hundreds of thousands of animal species that are increasingly threatened by anthropogenic disturbances. These animals host microbial communities at their surface, playing crucial roles for their fitness. However, the diversity of such microbiomes is mostly described in a few coral species and still poorly defined in other invertebrates and vertebrates. Given the diversity of animal microbiomes, and the diversity of host species inhabiting coral reefs, the contribution of such microbiomes to the total microbial diversity of coral reefs could be important, yet potentially vulnerable to the loss of animal species. Analysis of the surface microbiome from 74 taxa, including teleost fishes, hard and soft corals, crustaceans, echinoderms, bivalves and sponges, revealed that more than 90% of their prokaryotic phylogenetic richness was specific and not recovered in surrounding plankton. Estimate of the total richness associated with coral reef animal surface microbiomes reached up to 2.5% of current estimates of Earth prokaryotic diversity. Therefore, coral reef animal surfaces should be recognized as a hotspot of marine microbial diversity. Loss of the most vulnerable reef animals expected under present-day scenarios of reef degradation would induce an erosion of 28% of the prokaryotic richness, with unknown consequences on coral reef ecosystem functioning.
Collapse
Affiliation(s)
- Marlène Chiarello
- MARBEC, Université de Montpellier, CNRS, Ifremer, IRD, Montpellier, France
| | | | - Nicholas A J Graham
- Lancaster Environment Centre, Lancaster University, Library Avenue, Lancaster LA1 4YQ, UK
| | - Thomas Claverie
- MARBEC, Université de Montpellier, CNRS, Ifremer, IRD, Montpellier, France.,Département Sciences et Technologie, Centre Universitaire de Formation et de Recherche de Mayotte, Route nationale 3, BP53, 97660 Dembeni, France
| | - Elliott Sucré
- MARBEC, Université de Montpellier, CNRS, Ifremer, IRD, Montpellier, France.,Département Sciences et Technologie, Centre Universitaire de Formation et de Recherche de Mayotte, Route nationale 3, BP53, 97660 Dembeni, France
| | - Corinne Bouvier
- MARBEC, Université de Montpellier, CNRS, Ifremer, IRD, Montpellier, France
| | | | | | - Yvan Bettarel
- MARBEC, Université de Montpellier, CNRS, Ifremer, IRD, Montpellier, France
| | - Sébastien Villéger
- MARBEC, Université de Montpellier, CNRS, Ifremer, IRD, Montpellier, France
| | - Thierry Bouvier
- MARBEC, Université de Montpellier, CNRS, Ifremer, IRD, Montpellier, France
| |
Collapse
|
27
|
Macagno N, Bouvier C, Le Loarer F. [Fine-needle biopsy of soft-tissue neoplasms: Case No.1]. Ann Pathol 2020; 40:256-262. [PMID: 32340755 DOI: 10.1016/j.annpat.2020.02.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2020] [Revised: 01/24/2020] [Accepted: 02/10/2020] [Indexed: 10/24/2022]
Affiliation(s)
- Nicolas Macagno
- Anatomie pathologique, APHM, Aix Marseille Université, CHU de Timone, rue Saint-Pierre, 13385 Marseille, France.
| | - Corinne Bouvier
- Anatomie pathologique, APHM, Aix Marseille Université, CHU de Timone, rue Saint-Pierre, 13385 Marseille, France
| | | |
Collapse
|
28
|
Richert I, Gomez-Brouchet A, Bouvier C, Du Bouexic De Pinieux G, KaranianM A, Blay JY, Dutour A. Corrigendum to: ``The immune landscape of chondrosarcoma reveals an immunosuppressive environment in the dedifferentiated subtypes and exposes CSFR1+ macrophages as a promising therapeutic target.'' J Bone Oncol. 2020 Feb; 20: 100271. J Bone Oncol 2020; 22:100287. [PMID: 32274326 DOI: 10.1016/j.jbo.2020.100287] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
Abstract
[This corrects the article DOI: 10.1016/j.jbo.2019.100271.].
Collapse
Affiliation(s)
- Iseulys Richert
- CRCL, Cell death and pediatric cancers team, U1052, UMR5286 Lyon, France
| | - Anne Gomez-Brouchet
- Department of Pathology, IUCT-Oncopole, CHU of Toulouse, Université de Toulouse 3. UMR1037 INSERM-Université Toulouse 3-ERL5294 CNRS, Toulouse, France
| | - Corinne Bouvier
- Department of pathology, APHM La Timone, Aix Marseille University, MMG, France
| | | | - Arie KaranianM
- Department of pathology, Centre Léon Bérard, Lyon, France
| | - Jean-Yves Blay
- CRCL, Cell death and pediatric cancers team, U1052, UMR5286 Lyon, France.,Department of pathology, Centre Léon Bérard, Lyon, France
| | - Aurélie Dutour
- CRCL, Cell death and pediatric cancers team, U1052, UMR5286 Lyon, France
| |
Collapse
|
29
|
Macagno N, Bouvier C, Le Loarer F. [Pleomorphic soft tissue tumor: Case No. 6]. Ann Pathol 2020; 40:293-299. [PMID: 32147192 DOI: 10.1016/j.annpat.2020.01.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2020] [Revised: 01/24/2020] [Accepted: 01/24/2020] [Indexed: 10/24/2022]
Affiliation(s)
- Nicolas Macagno
- Aix Marseille université, anatomie pathologique, CHU Timone, AP-HM, rue Saint-Pierre, 13385 Marseille, France.
| | - Corinne Bouvier
- Aix Marseille université, anatomie pathologique, CHU Timone, AP-HM, rue Saint-Pierre, 13385 Marseille, France
| | | |
Collapse
|
30
|
Le Loarer F, Cleven AHG, Bouvier C, Castex MP, Romagosa C, Moreau A, Salas S, Bonhomme B, Gomez-Brouchet A, Laurent C, Le Guellec S, Audard V, Giraud A, Ramos-Oliver I, Cleton-Jansen AM, Savci-Heijink DC, Kroon HM, Baud J, Pissaloux D, Pierron G, Sherwood A, Coindre JM, Bovée JVMG, Larousserie F, Tirode F. A subset of epithelioid and spindle cell rhabdomyosarcomas is associated with TFCP2 fusions and common ALK upregulation. Mod Pathol 2020; 33:404-419. [PMID: 31383960 DOI: 10.1038/s41379-019-0323-8] [Citation(s) in RCA: 70] [Impact Index Per Article: 17.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2019] [Revised: 06/19/2019] [Accepted: 06/19/2019] [Indexed: 12/14/2022]
Abstract
Rhabdomyosarcomas with TFCP2 fusions represent an emerging subtype of tumors, initially discovered by RNA-sequencing. We report herein the clinicopathological, transcriptional, and genomic features of a series of 14 cases. Cases were retrospectively and prospectively recruited and studied by immunohistochemistry (MYF4, MYOD1, S100, AE1/E3, ALK), fluorescence in situ hybridization with TFCP2 break-apart probe (n = 10/14), array-comparative genomic hybridization (Agilent), whole RNA-sequencing (Truseq Exome, Illumina), or anchored multiplex PCR-based targeted next-generation sequencing (Archer® FusionPlex® Sarcoma kit). Patient's age ranged between 11 and 86 years, including 5 pediatric cases. Tumors were located in the bone (n = 12/14) and soft tissue (n = 2/14). Most bone tumors invaded surrounding soft tissue. Craniofacial bones were over-represented (n = 8/12). Median survival was 8 months and five patients are currently alive with a median follow-up of 20 months. Most tumors displayed a mixed spindle cell and epithelioid pattern with frequent vesicular nuclei. All tumors expressed keratins and showed a rhabdomyogenic phenotype (defined as expression of MYF4 and/or MYOD1). ALK was overexpressed in all but three cases without underlying ALK fusion on break-apart FISH (n = 5) nor next-generation sequencing (n = 14). ALK upregulation was frequently associated with an internal deletion at genomic level. TFCP2 was fused in 5' either to EWSR1 (n = 6) or FUS (n = 8). EWSR1 was involved in both soft tissue cases. FISH with TFCP2 break-apart probe was positive in all tested cases (n = 8), including one case with unbalanced signal. On array-CGH, all tested tumors displayed complex genetic profiles with genomic indexes ranging from 13 to 107.55 and recurrent CDKN2A deletions. FET-TFCP2 rhabdomyosarcomas clustered together and distinctly from other rhabdomyosarcomas subgroups. Altogether, our data confirm and expand the spectrum of the new family of FET-TFCP2 rhabdomyosarcomas, which are associated with a predilection for the craniofacial bones, an aggressive course, and recurrent pathological features. Their association with ALK overexpression might represent a therapeutic vulnerability.
Collapse
Affiliation(s)
- François Le Loarer
- Department of Pathology, Institut Bergonié, Bordeaux, France. .,Université de Bordeaux, Talence, France. .,INSERM U1218 ACTION, Institut Bergonie, Bordeaux, France.
| | - Arjen H G Cleven
- Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
| | - Corinne Bouvier
- Department of Pathology, Hôpital La Timone, APHM, Marseille, France
| | | | - Cleofe Romagosa
- Department of Pathology, Vall d'Hebron University Hospital, Barcelona, Spain
| | - Anne Moreau
- Department of Pathology, CHU Nantes, Nantes, France
| | | | | | - Anne Gomez-Brouchet
- Department of Pathology, Institut Claudius Regaud-Institut universitaire du cancer-Oncopôle, Toulouse, France
| | - Camille Laurent
- Department of Pathology, Institut Claudius Regaud-Institut universitaire du cancer-Oncopôle, Toulouse, France
| | - Sophie Le Guellec
- Department of Pathology, Institut Claudius Regaud-Institut universitaire du cancer-Oncopôle, Toulouse, France
| | - Virginie Audard
- Department of Pathology, Hôpital Cochin, APHP, Paris, France
| | - Antoine Giraud
- Department of Clinical Trials, Institut Bergonié, Bordeaux, France
| | - Irma Ramos-Oliver
- Department of Pathology, Vall d'Hebron University Hospital, Barcelona, Spain
| | | | | | - Herman M Kroon
- Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands
| | - Jessica Baud
- Université de Bordeaux, Talence, France.,INSERM U1218 ACTION, Institut Bergonie, Bordeaux, France
| | - Daniel Pissaloux
- Department of Biopathologie, Centre Léon Bérard, Lyon, France.,Univ Lyon, Université Claude Bernard Lyon 1, CNRS 5286, INSERM U1052, Cancer Research Center of Lyon, Lyon, France
| | - Gaëlle Pierron
- Department of Biology of Tumors, Institut Curie, Paris, France
| | - Anand Sherwood
- Department of Conservative Dentistry and Endodontics, CSI College of Dental Sciences, Madurai, India
| | - Jean Michel Coindre
- Department of Pathology, Institut Bergonié, Bordeaux, France.,Université de Bordeaux, Talence, France.,INSERM U1218 ACTION, Institut Bergonie, Bordeaux, France
| | - Judith V M G Bovée
- Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
| | | | - Franck Tirode
- Univ Lyon, Université Claude Bernard Lyon 1, CNRS 5286, INSERM U1052, Cancer Research Center of Lyon, Lyon, France
| |
Collapse
|
31
|
Marques R, Darnaude AM, Crochemore S, Bouvier C, Bonnet D. Molecular approach indicates consumption of jellyfish by commercially important fish species in a coastal Mediterranean lagoon. Mar Environ Res 2019; 152:104787. [PMID: 31522875 DOI: 10.1016/j.marenvres.2019.104787] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/04/2019] [Revised: 09/05/2019] [Accepted: 09/07/2019] [Indexed: 06/10/2023]
Abstract
Until recently, jellyfish have been ignored as an important source of food, due to their low nutritional value. Here, quantitative PCR was used to detect and quantify the DNA of the jellyfish Aurelia coerulea in the gut contents of commercially important fish species from the Thau Lagoon. Individuals from five fish species were collected during two different periods: the bloom period, when the pelagic stages of A. coerulea are abundant, and the post-bloom period, when only the benthic stage - polyps - is present in the lagoon. The DNA of A. coerulea was detected in the guts of 41.9% of the fish analysed, belonging to four different species. The eel Anguilla anguilla and the seabream Sparus aurata were important jellyfish consumers during the bloom and post-bloom periods, respectively. These results provide new insights on the potential control of jellyfish populations and on jellyfish importance as a food source for exploited fishes.
Collapse
Affiliation(s)
- Raquel Marques
- MARBEC, Univ Montpellier, CNRS, Ifremer, IRD, Montpellier, France.
| | | | | | - Corinne Bouvier
- MARBEC, Univ Montpellier, CNRS, Ifremer, IRD, Montpellier, France
| | - Delphine Bonnet
- MARBEC, Univ Montpellier, CNRS, Ifremer, IRD, Montpellier, France
| |
Collapse
|
32
|
Richert I, Bouvier C, Gomez-Brouchet A, De Pinieux GDB, Marie K, Blay JY, Dutour A. The immune landscape of chondrosarcoma reveals an anti inflammatory environment. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz283.042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
33
|
Duffaud F, Blay JY, Italiano A, Bompas E, Rios M, Penel N, Mir O, Piperno-Neumann S, Chevreau C, Delcambre C, Bertucci F, Boudou Rouquette P, Vegas H, Perrin C, Thyss A, Schiffler C, Monard L, Bouvier C, Vidal V, Chabaud S. Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REG) in patients (pts) with locally advanced (LA) or metastatic relapsed chondrosarcoma (CS), on behalf of the French Sarcoma Group (FSG) and UNICANCER. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz394.088] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
34
|
Gomez-Brouchet A, Mascard E, Siegfried A, de Pinieux G, Gaspar N, Bouvier C, Aubert S, Marec-Bérard P, Piperno-Neumann S, Marie B, Larousserie F, Galant C, Fiorenza F, Anract P, Sales de Gauzy J, Gouin F. Assessment of resection margins in bone sarcoma treated by neoadjuvant chemotherapy: Literature review and guidelines of the bone group (GROUPOS) of the French sarcoma group and bone tumor study group (GSF-GETO/RESOS). Orthop Traumatol Surg Res 2019; 105:773-780. [PMID: 30962172 DOI: 10.1016/j.otsr.2018.12.015] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/20/2018] [Revised: 12/04/2018] [Accepted: 12/07/2018] [Indexed: 02/02/2023]
Abstract
BACKGROUND Standardized reports are essential to meeting the bone sarcoma reference center certification requirements of the French National Cancer Institute (INCa). The usual classifications of the Musculoskeletal Tumor Society (MSTS), the American Joint Committee on Cancer (AJCC/IUCC) TNM R classification and the American College of Pathologists, are inexact inasmuch as they fail to include chemotherapy impact on tumor cells in assessing surgical margins. This leads to inconsistent interpretation by teams managing bone sarcoma. The present literature analysis sought to assess the limitations of existing classifications for purposes of standardized reporting of the management of surgical specimens from patients with osteosarcoma or Ewing sarcoma receiving neoadjuvant chemotherapy, by addressing the following questions: 1) What is the prognostic value of margins and chemotherapy response in the classifications? 2) What are the histologic changes induced by chemotherapy, with what impact on interpretation of margins? METHOD A PubMed literature analysis was performed, targeting the prognostic value of resection margin assessment, in September 2018. French bone pathology group (Groupe français des pathologistes osseux) and international guidelines on bone specimen management were referred to so as select items for a standardized report. Eight of the 523 articles retrieved met the study eligibility criteria. RESULTS Minimal distance between tumor and surgical margin, with a>2mm threshold, seemed to be the optimal parameter for predicting local recurrence. Good chemotherapy response and appendicular skeletal location were associated with lower risk of local recurrence. None of the available classifications take into account the microscopic changes induced by chemotherapy in interpreting resection margins. DISCUSSION To standardize practice, GROUPOS developed a standardized report for bone sarcoma specimens, considering the histopathologic changes in the tumor after neoadjuvant chemotherapy. The TNM R system was adapted and a threshold of>2mm was chosen as an acceptable limit to qualify surgical resection as safe (R0). R1 status (≤2mm) was subdivided into subgroups a, b and c, to include margin measurement in relation to the post-chemotherapy scar: R1a, resection within the scar; R1b, resection in healthy tissue,≤2mm from the scar and/or residual viable cells; and R1c, resection within the lesion in contact with viable cells or within coagulation necrosis areas. The GROUPOS members drew up this standardized report so as to ensure a common language, improving bone sarcoma management in specialized centers. Reliable data can thus be established for national and international multicenter studies. LEVEL OF EVIDENCE IV.
Collapse
Affiliation(s)
- Anne Gomez-Brouchet
- Département de pathologie, IUCT-oncopole, CHU de Toulouse and université de Toulouse, 1, avenue Irène Joliot Curie, 31059 Toulouse cedex 9, France.
| | - Eric Mascard
- Département de chirurgie orthopédique pédiatrique, hôpital-Necker, 149, rue de Sèvres, 75015 Paris, France
| | - Aurore Siegfried
- Département de pathologie, IUCT-oncopole, CHU de Toulouse and université de Toulouse, 1, avenue Irène Joliot Curie, 31059 Toulouse cedex 9, France
| | - Gonzague de Pinieux
- Service d'anatomie et cytologie pathologiques et université de Tours, CHRU de Tours, Avenue de la République, 37170 Chambray-lès-Tours, France
| | - Nathalie Gaspar
- Département de cancérologie de l'enfant et l'adolescent, Gustave-Roussy cancer campus, 114, rue Edouard Vaillant, 94800 Villejuif, France
| | - Corinne Bouvier
- Département de pathologie, CHU la Timone, 278, rue Saint-Pierre, 13005 Marseille, France
| | - Sébastien Aubert
- Université de lille - institut de pathologie, centre de biologie pathologie, 1, rue Philippe Marache, 59000 Lille, France
| | - Perrine Marec-Bérard
- Département d' oncologie pédiatrique, IHOPe/Centre Léon Bérard, 28, promenade Léa et Napoléon Bullukian, 69008 Lyon, France
| | | | - Béatrice Marie
- Département de Pathologie, CHU Nancy, 25, rue Lionnois, 54000 Nancy, France
| | - Frédérique Larousserie
- Service de pathologie et université Paris Descartes, AP-HP, hôpital Cochin, 27, rue du Faubourg Saint-Jacques, 75014 Paris, France
| | - Christine Galant
- Service d'anatomie pathologique des cliniques universitaires Saint-Luc, 10, avenue Hippocrate, 1200 Brussels, Belgium
| | - Fabrice Fiorenza
- Département de chirurgie orthopédique, CHU de Limoges, 2, avenue Martin Luther King, 87000 Limoges, France
| | - Philippe Anract
- Département de chirurgie orthopédique, CHU de Cochin, AP-HP, 27, rue du Faubourg Saint-Jacques, 75014 Paris, France
| | - Jérôme Sales de Gauzy
- Département de chirurgie orthopédique pédiatrique, hôpital-Mère-Enfant, CHU Toulouse, 330, avenue de Grande Bretagne, 31300 Toulouse, France
| | - François Gouin
- Centre Léon-Bérard, CHU Nantes, Nantes/Inserm, UMR 1238, Phy-Os, université de Nantes, 28, rue Laennec, 69008 Lyon France
| | | |
Collapse
|
35
|
Baudet M, Daugareil C, Laulom P, Bouvier C, Hubert J. [Therapeutic education in primary cardiovascular prevention]. Ann Cardiol Angeiol (Paris) 2019; 68:49-52. [PMID: 30686470 DOI: 10.1016/j.ancard.2018.08.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2018] [Accepted: 08/24/2018] [Indexed: 06/09/2023]
Abstract
BACKGROUND As primary prevention against cardiovascular diseases, Patient Therapeutic Education helps to develop a protective lifestyle within a socioeconomic context where risk factors abound. PATIENTS AND METHODS Patient Therapeutic Education offers those eager to protect their cardiovascular health a program of six workshops. Upon enrolment, a Program aide conducts an educational diagnosis with the patient, specific to each workshop theme, so that he might understand the clinical, socio-professional, cognitive and psycho-affective dimensions. An evaluation of each workshop is requested from participants in the form of open and closed questions. RESULTS The study comprised 2225people, majority women (79%), relatively old (age 63.9for women, 66.3for men), most often retired (65%). An analysis of the educational diagnosis notes a great frequency of classic risk factors; a good knowledge of the factors favoring them contrasting with the weak means implemented in everyday life to reduce their impact; the great majority of participants (68%) believe they have a well balanced diet; patients are greatly involved in their own health, with a slight external locus involving the general practitioner, the immediate entourage and society. The notes of the evaluation are usually maximum. CONCLUSION Patient Therapeutic Education arouses strong interest in the public, allows a personalized approach that optimizes learning, increases knowledge and facilitates the use of new protective practices.
Collapse
Affiliation(s)
- M Baudet
- Maison du cœur, centre hospitalier de Dax Côte d'Argent, 7, rue de Borda, 40300 Dax, France.
| | - C Daugareil
- Maison du cœur, centre hospitalier de Dax Côte d'Argent, 7, rue de Borda, 40300 Dax, France
| | - P Laulom
- Maison du cœur, centre hospitalier de Dax Côte d'Argent, 7, rue de Borda, 40300 Dax, France
| | - C Bouvier
- Maison du cœur, centre hospitalier de Dax Côte d'Argent, 7, rue de Borda, 40300 Dax, France
| | - J Hubert
- Maison du cœur, centre hospitalier de Dax Côte d'Argent, 7, rue de Borda, 40300 Dax, France
| |
Collapse
|
36
|
Duffaud F, Mir O, Boudou-Rouquette P, Piperno-Neumann S, Penel N, Bompas E, Delcambre C, Kalbacher E, Italiano A, Collard O, Chevreau C, Saada E, Isambert N, Delaye J, Schiffler C, Bouvier C, Vidal V, Chabaud S, Blay JY. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol 2018; 20:120-133. [PMID: 30477937 DOI: 10.1016/s1470-2045(18)30742-3] [Citation(s) in RCA: 194] [Impact Index Per Article: 32.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2018] [Revised: 09/27/2018] [Accepted: 09/28/2018] [Indexed: 10/27/2022]
Abstract
BACKGROUND Regorafenib has proven activity in patients with pretreated gastrointestinal stromal tumours and colorectal and hepatocellular carcinoma. We designed REGOBONE to assess the efficacy and safety of regorafenib for patients with progressive metastatic osteosarcoma and other bone sarcomas. This trial comprised four parallel independent cohorts: osteosarcoma, Ewing sarcoma, chondrosarcoma, and chordoma. In this Article, we report the results of the osteosarcoma cohort. METHODS In this non-comparative, double-blind, placebo-controlled, phase 2 trial, patients aged 10 years or older with histologically confirmed osteosarcoma whose disease had progressed after treatment with one to two previous lines of chemotherapy for metastatic disease and an Eastern Cooperative Oncology Group performance status of 0 or 1 were enrolled. Patients were randomly assigned (2:1) to receive either oral regorafenib (160 mg/day, for 21 of 28 days) or matching placebo. Patients in both groups also received best supportive care. Randomisation was done using a web-based system and was stratified (permuted block) by age at inclusion (<18 vs ≥18 years old). Investigators and patients were masked to treatment allocation. Patients in the placebo group, after centrally confirmed progressive disease, could cross over to receive regorafenib. The primary endpoint was the proportion of patients without disease progression at 8 weeks. Analyses were done by modified intention to treat (ie, patients without any major entry criteria violation who initiated masked study drug treatment were included). All participants who received at least one dose of study drug were included in the safety analyses. This study is registered with ClinicalTrials.gov, number NCT02389244, and the results presented here are the final analysis of the osteosarcoma cohort (others cohorts are ongoing). FINDINGS Between Oct 10, 2014, and April 4, 2017, 43 adult patients were enrolled from 13 French comprehensive cancer centres. All patients received at least one dose of assigned treatment and were evaluable for safety; five patients were excluded for major protocol violations (two in the placebo group and three in the regorafenib group), leaving 38 patients who were evaluable for efficacy (12 in the placebo group and 26 in the regorafenib group). 17 of 26 patients (65%; one-sided 95% CI 47%) in the regorafenib group were non-progressive at 8 weeks compared with no patients in the placebo group. Ten patients in the placebo group crossed over to receive open-label regorafenib after centrally confirmed disease progression. 13 treatment-related serious adverse events occurred in seven (24%) of 29 patients in the regorafenib group versus none of 14 patients in the placebo group. The most common grade 3 or worse treatment-related adverse events during the double-blind period of treatment included hypertension (in seven [24%] of 29 patients in the regorafenib group vs none in the placebo group), hand-foot skin reaction (three [10%] vs none), fatigue (three [10%] vs one [3%]), hypophosphataemia (three [10%] vs none), and chest pain (three [10%] vs none). No treatment-related deaths occurred. INTERPRETATION Regorafenib demonstrated clinically meaningful antitumour activity in adult patients with recurrent, progressive, metastatic osteosarcoma after failure of conventional chemotherapy, with a positive effect on delaying disease progression. Regorafenib should be further evaluated in the setting of advanced disease as well as potentially earlier in the disease course for patients at high risk of relapse. Regorafenib might have an important therapeutic role as an agent complementary to standard cytotoxic chemotherapy in the therapeutic armamentarium against osteosarcoma. FUNDING Bayer HealthCare.
Collapse
Affiliation(s)
- Florence Duffaud
- Medical Oncology Unit, Aix Marseille University, APHM Hôpital La Timone, Marseille, France.
| | - Olivier Mir
- Medical Oncology Department, Gustave Roussy, Villejuif, France
| | | | | | - Nicolas Penel
- Medical Oncology Department, Centre Oscar Lambret and Lille University Hospital, Lille, France
| | - Emanuelle Bompas
- Medical Oncology Department, Centre René Gauduchau, Saint Herblain, France
| | | | - Elsa Kalbacher
- Medical Oncology Department, CHRU Jean Minjoz, Besançon, France
| | - Antoine Italiano
- Medical Oncology Department, Institut Bergonié, Bordeaux, France
| | - Olivier Collard
- Medical Oncology Department, Institut de Cancérologie de la Loire Lucien Neuwirth, St Priest en Jarez, France
| | - Christine Chevreau
- Medical Oncology Department, Institut Universitaire de Cancérologie de Toulouse, Oncopole, Toulouse, France
| | - Esma Saada
- Medical Oncology Department, Centre Antoine Lacassagne, Nice, France
| | | | | | | | - Corinne Bouvier
- Pathology Department, Aix Marseille University, APHM Hôpital La Timone, Marseille, France
| | - Vincent Vidal
- Radiology Department, Aix Marseille University, APHM Hôpital La Timone, Marseille, France
| | - Sylvie Chabaud
- Department of Statistics, Centre Léon Bérard, Lyon, France
| | - Jean-Yves Blay
- Medical Oncology Department, Centre Léon Bérard, Lyon, France
| | | |
Collapse
|
37
|
Chiarello M, Auguet JC, Bettarel Y, Bouvier C, Claverie T, Graham NAJ, Rieuvilleneuve F, Sucré E, Bouvier T, Villéger S. Skin microbiome of coral reef fish is highly variable and driven by host phylogeny and diet. Microbiome 2018; 6:147. [PMID: 30143055 PMCID: PMC6109317 DOI: 10.1186/s40168-018-0530-4] [Citation(s) in RCA: 73] [Impact Index Per Article: 12.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/16/2018] [Accepted: 08/12/2018] [Indexed: 05/10/2023]
Abstract
BACKGROUND The surface of marine animals is covered by abundant and diversified microbial communities, which have major roles for the health of their host. While such microbiomes have been deeply examined in marine invertebrates such as corals and sponges, the microbiomes living on marine vertebrates have received less attention. Specifically, the diversity of these microbiomes, their variability among species, and their drivers are still mostly unknown, especially among the fish species living on coral reefs that contribute to key ecosystem services while they are increasingly affected by human activities. Here, we investigated these knowledge gaps analyzing the skin microbiome of 138 fish individuals belonging to 44 coral reef fish species living in the same area. RESULTS Prokaryotic communities living on the skin of coral reef fishes are highly diverse, with on average more than 600 OTUs per fish, and differ from planktonic microbes. Skin microbiomes varied between fish individual and species, and interspecific differences were slightly coupled to the phylogenetic affiliation of the host and its ecological traits. CONCLUSIONS These results highlight that coral reef biodiversity is greater than previously appreciated, since the high diversity of macro-organisms supports a highly diversified microbial community. This suggest that beyond the loss of coral reefs-associated macroscopic species, anthropic activities on coral reefs could also lead to a loss of still unexplored host-associated microbial diversity, which urgently needs to be assessed.
Collapse
Affiliation(s)
- Marlène Chiarello
- Marine Biodiversity, Exploitation and Conservation (MARBEC), Université de Montpellier, CNRS, IRD, IFREMER, Place Eugène Bataillon, Case 093, 34 095, Montpellier Cedex 5, France.
- Laboratoire Ecologie Fonctionnelle et Environnement, Université de Toulouse, Toulouse, France.
| | - Jean-Christophe Auguet
- Marine Biodiversity, Exploitation and Conservation (MARBEC), Université de Montpellier, CNRS, IRD, IFREMER, Place Eugène Bataillon, Case 093, 34 095, Montpellier Cedex 5, France
| | - Yvan Bettarel
- Marine Biodiversity, Exploitation and Conservation (MARBEC), Université de Montpellier, CNRS, IRD, IFREMER, Place Eugène Bataillon, Case 093, 34 095, Montpellier Cedex 5, France
| | - Corinne Bouvier
- Marine Biodiversity, Exploitation and Conservation (MARBEC), Université de Montpellier, CNRS, IRD, IFREMER, Place Eugène Bataillon, Case 093, 34 095, Montpellier Cedex 5, France
| | - Thomas Claverie
- Marine Biodiversity, Exploitation and Conservation (MARBEC), Université de Montpellier, CNRS, IRD, IFREMER, Place Eugène Bataillon, Case 093, 34 095, Montpellier Cedex 5, France
- Centre Universitaire de Formation et de Recherche de Mayotte, Dembéni, Mayotte, France
| | | | - Fabien Rieuvilleneuve
- Marine Biodiversity, Exploitation and Conservation (MARBEC), Université de Montpellier, CNRS, IRD, IFREMER, Place Eugène Bataillon, Case 093, 34 095, Montpellier Cedex 5, France
| | - Elliot Sucré
- Marine Biodiversity, Exploitation and Conservation (MARBEC), Université de Montpellier, CNRS, IRD, IFREMER, Place Eugène Bataillon, Case 093, 34 095, Montpellier Cedex 5, France
- Centre Universitaire de Formation et de Recherche de Mayotte, Dembéni, Mayotte, France
| | - Thierry Bouvier
- Marine Biodiversity, Exploitation and Conservation (MARBEC), Université de Montpellier, CNRS, IRD, IFREMER, Place Eugène Bataillon, Case 093, 34 095, Montpellier Cedex 5, France
| | - Sébastien Villéger
- Marine Biodiversity, Exploitation and Conservation (MARBEC), Université de Montpellier, CNRS, IRD, IFREMER, Place Eugène Bataillon, Case 093, 34 095, Montpellier Cedex 5, France
| |
Collapse
|
38
|
Bernard F, Troude L, Bouvier C, Roche PH. Le granulome réparateur à cellules géantes : un diagnostic différentiel exceptionnel pour une lésion lytique de l’os temporal. Neurochirurgie 2018. [DOI: 10.1016/j.neuchi.2018.05.060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
39
|
Duffaud F, Blay JY, Mir O, Boudou-Rouquette P, Piperno-Neumann S, Penel N, Bompas E, Delcambre C, Kalbacher E, Italiano A, Collard O, Chevreau C, Thyss A, Isambert N, Delaye J, De Sousa Carvalho N, Schiffler C, Bouvier C, Vidal V, Chabaud S. Results of randomized, placebo (PL)-controlled phase II study evaluating efficacy and safety of regorafenib (REG) in patients (pts) with metastatic osteosarcoma (metOS), on behalf of the French Sarcoma Group (FSG) and Unicancer. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.11504] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | - Olivier Mir
- Gustave Roussy Cancer Campus, Villejuif, France
| | | | | | | | | | | | | | | | - Olivier Collard
- Institut de Cancérologie de la Loire, St. Priest En Jarez, France
| | | | | | - Nicolas Isambert
- Service d'oncologie médicale CLCC Georges-François Leclerc, Dijon, France
| | | | | | | | - Corinne Bouvier
- Assistance Publique - Hopitaux De Marseille, Marseille, France
| | - Vincent Vidal
- Assistance Publique - Hôpitaux de Marseille, Marseille, France
| | | |
Collapse
|
40
|
Lavit E, Lagarde A, Bouvier C, Fabre A, Brouchet A, Gentet JC, Atkinson A, Duffaud F, Olschwang S, Salas S. Next generation sequencing in non metastatic high grade pediatric osteosarcoma: A useful tool to identify new therapeutic targets. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.e24235] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | - Corinne Bouvier
- Assistance Publique - Hopitaux De Marseille, Marseille, France
| | - Aurelie Fabre
- UMR S-910 INSERM ; (3) Department of Medical Genetics. Aix-Marseille University - Assistance Publique Hopitaux de Marseille, Marseille, France
| | | | | | | | | | - Sylviane Olschwang
- UMR S-910 INSERM. Medical genetics and functional genomics ; (3) Department of Medical Genetics. Aix-Marseille University - Assistance Publique Hopitaux de Marseille, Marseille, France
| | - Sebastien Salas
- CEPCM Assistance Publique des Hôpitaux de Marseille, Marseille, France
| |
Collapse
|
41
|
Macagno N, Vogels R, Appay R, Colin C, Mokhtari K, Küsters B, Wesseling P, Figarella-Branger D, Flucke U, Bouvier C. Grading of meningeal solitary fibrous tumors/hemangiopericytomas: analysis of the prognostic value of the Marseille Grading System in a cohort of 132 patients. Brain Pathol 2018; 29:18-27. [PMID: 29600523 DOI: 10.1111/bpa.12613] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2018] [Accepted: 03/12/2018] [Indexed: 12/18/2022] Open
Abstract
The finding that meningeal solitary fibrous tumors (SFTs) and meningeal hemangiopericytomas (HPCs) are both characterized by NAB2-STAT6 gene fusion has pushed their inclusion in the WHO 2016 Classification of tumors of the central nervous system (CNS) as different manifestations of the same entity. Given that the clinical behavior of the CNS SFT/HPC spectrum ranges from benign to malignant, it is presently unclear whether the grading criteria are still adequate. Here, we present the results of a study that analyzed the prognostic value of an updated version of the Marseille Grading System (MGS) in a retrospectively assembled cohort of 132 primary meningeal SFTs/HPCs with nuclear overexpression of STAT6. The median patient follow-up was 64 months (range 4-274 months); 73 cases (55%) were MGS I, 50 cases (38%) MGS II and 9 cases (7%) were MGS III. Progression-free survival (PFS) and disease-specific survival (DSS) were investigated using univariate analysis: the prognostic factors for PFS included MGS, extent of surgery, radiotherapy, chemotherapy and mitotic activity ≥5/10 high-power field (HPF). Moreover, MGS, radiotherapy, mitotic activity ≥5/10 HPF, and necrosis were the prognostic factors measured for DSS. In multivariate analysis, extent of surgery, mitotic activity ≥5/10 HPF, MGS I and MGS III were the independent prognostic factors measured for PFS while necrosis, MGS III and radiotherapy were the independent prognostic factors for DSS. In conclusion, our results show that assessing the malignancy risk of SFT/HPC should not rely on one single criterion like mitotic activity. Therefore, MGS is useful as it combines the value of different criteria. In particular, the combination of a high mitotic activity and necrosis (MGS III) indicates a particularly poor prognosis.
Collapse
Affiliation(s)
- Nicolas Macagno
- Department of Pathology and Neuropathology, Timone Hospital, Marseille, France.,INSERM UMR911, Aix-Marseille University (AMU), Marseille, France
| | - Rob Vogels
- Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.,Department of Pathology, Stichting PAMM, Eindhoven, The Netherlands
| | - Romain Appay
- Department of Pathology and Neuropathology, Timone Hospital, Marseille, France.,INSERM UMR911, Aix-Marseille University (AMU), Marseille, France
| | - Carole Colin
- INSERM UMR911, Aix-Marseille University (AMU), Marseille, France
| | - Karima Mokhtari
- Department of Neuropathology, Pitié-Salpêtrière Hospital, Paris, France
| | | | | | - Benno Küsters
- Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.,Department of Pathology, Maastricht University Medical Center, Maastricht, The Netherlands
| | - Pieter Wesseling
- Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands.,Department of Pathology, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.,University Medical Center, Utrecht, The Netherlands
| | - Dominique Figarella-Branger
- Department of Pathology and Neuropathology, Timone Hospital, Marseille, France.,INSERM UMR911, Aix-Marseille University (AMU), Marseille, France
| | - Uta Flucke
- Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.,Department of Pathology, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.,University Medical Center, Utrecht, The Netherlands
| | - Corinne Bouvier
- Department of Pathology and Neuropathology, Timone Hospital, Marseille, France.,INSERM UMR911, Aix-Marseille University (AMU), Marseille, France
| |
Collapse
|
42
|
Salas S, Resseguier N, Blay JY, Le Cesne A, Italiano A, Chevreau C, Rosset P, Isambert N, Soulie P, Cupissol D, Delcambre C, Bay JO, Dubray-Longeras P, Krengli M, De Bari B, Villa S, Kaanders JHAM, Torrente S, Pasquier D, Thariat JO, Myroslav L, Sole CV, Dincbas HF, Habboush JY, Zilli T, Dragan T, Khan R K, Ugurluer G, Cena T, Duffaud F, Penel N, Bertucci F, Ranchere-Vince D, Terrier P, Bonvalot S, Macagno N, Lemoine C, Lae M, Coindre JM, Bouvier C. Prediction of local and metastatic recurrence in solitary fibrous tumor: construction of a risk calculator in a multicenter cohort from the French Sarcoma Group (FSG) database. Ann Oncol 2018; 28:1979-1987. [PMID: 28838212 DOI: 10.1093/annonc/mdx250] [Citation(s) in RCA: 83] [Impact Index Per Article: 13.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Background Solitary fibrous tumors (SFT) are rare unusual ubiquitous soft tissue tumors that are presumed to be of fibroblastic differentiation. At present, the challenge is to establish accurate prognostic factors. Patients and methods A total of 214 consecutive patients with SFT diagnosed in 24 participating cancer centers were entered into the European database (www.conticabase.org) to perform univariate and multivariate analysis for overall survival (OS), local recurrence incidence (LRI) and metastatic recurrence incidence (MRI) by taking competing risks into account. A prognostic model was constructed for LRI and MRI. Internal and external validations of the prognostic models were carried out. An individual risk calculator was carried out to quantify the risk of both local and metastatic recurrence. Results We restricted our analysis to 162 patients with local disease. Twenty patients (12.3%) were deceased at the time of analysis and the median OS was not reached. The LRI rates at 10 and 20 years were 19.2% and 38.6%, respectively. The MRI rates at 10 and 20 years were 31.4% and 49.8%, respectively. Multivariate analysis retained age and mitotic count tended to significance for predicting OS. The factors influencing LRI were viscera localization, radiotherapy and age. Mitotic count, tumor localization other than limb and age had independent values for MRI. Three prognostic groups for OS were defined based on the number of unfavorable prognostic factors and calculations were carried out to predict the risk of local and metastatic recurrence for individual patients. Conclusion LRI and MRI rates increased between 10 and 20 years so relapses were delayed, suggesting that long-term monitoring is useful. This study also shows that different prognostic SFT sub-groups could benefit from different therapeutic strategies and that use of a survival calculator could become standard practice in SFTs to individualize treatment based on the clinical situation.
Collapse
Affiliation(s)
- S Salas
- Department of Medicine, Timone Hospital, Marseille.,Aix Marseille University, Marseille
| | - N Resseguier
- Support Unit for Clinical Research and Economic Evaluatin, Timone Hospital, Marseille
| | - J Y Blay
- Department of Medicine, Leon Berard Center, Lyon
| | - A Le Cesne
- Department of Medicine, Gustave Roussy Institute, Villejuif
| | - A Italiano
- Department of Medicine, Bergonié Institute, Bordeaux
| | - C Chevreau
- Department of Medicine, Claudius Regaud Institute, Toulouse
| | - P Rosset
- Department of Medicine, CHU, Tours
| | - N Isambert
- Department of Medicine, Georges-François Leclerc Institute, Dijon
| | - P Soulie
- Department of Medicine, Paul Papin Institute, Angers
| | - D Cupissol
- Department of Medicine, Val d'Aurelle Institute, Montpellier
| | - C Delcambre
- Department of Medicine, François-Baclesse Institute, Caen
| | - J O Bay
- Department of Medicine, Jean Perrin Institute, Clermont-Ferrand, France
| | - P Dubray-Longeras
- Department of Medicine, Jean Perrin Institute, Clermont-Ferrand, France
| | - M Krengli
- Department of Radiotherapy, University Hospital, Novara, Italy
| | - B De Bari
- Department of Radiotherapy, CHU Vaudois, Lausanne, Switzerland
| | - S Villa
- Department of Radiotherapy, Catalan Institute of Oncology, Badalona Catalonia, Spain
| | - J H A M Kaanders
- Department of Radiotherapy, Radboud University Medical Center, Nijmegen, The Netherlands
| | - S Torrente
- Department of Radiotherapy, University Hospital, Novara, Italy
| | - D Pasquier
- Department of Radiotherapy, Centre Oscar Lambret, Lille
| | - J O Thariat
- Department of Radiotherapy, Centre Antoine-Lacassagne, Nice, France
| | - L Myroslav
- Department of Radiotherapy, Rambam HCC, Haifa, Israel
| | - C V Sole
- Department of Radiotherapy, Clinica Instituto de Radiomedicina (IRAM), Santiago, Chile
| | - H F Dincbas
- Department of Radiotherapy, Cerrahpasa Medical Faculty, Istanbul, Turkey
| | - J Y Habboush
- Department of Radiotherapy, Mayo Clinic, Jacksonville, USA
| | - T Zilli
- Department of Radiotherapy, HUG, Geneva, Switzerland
| | - T Dragan
- Department of Radiotherapy, Institut J. Bordet Brussels, Brussels, Belgium
| | - K Khan R
- Department of Radiotherapy, CHVR, Sion, Switzerland
| | - G Ugurluer
- Department of Radiotherapy, Adana Hospital, Adana, Turkey
| | - T Cena
- Department of Medical Statistics, University of Piemonte Orientale, Novara, Italy
| | - F Duffaud
- Department of Medicine, Timone Hospital, Marseille
| | - N Penel
- Department of Medicine, Oscar Lambret Institute, Lille
| | - F Bertucci
- Department of Medicine, Paoli Calmette Institute, Marseille
| | | | - P Terrier
- Department of Pathology, Gustave Roussy Institute, Villejuif
| | - S Bonvalot
- Department of Surgery, Institut Curie, PSL University, Paris
| | - N Macagno
- Department of Pathology, Timone Hospital, Marseille
| | - C Lemoine
- Support Unit for Clinical Research and Economic Evaluatin, Timone Hospital, Marseille
| | - M Lae
- Department of Pathology, Curie Institute, Paris
| | - J M Coindre
- Department of Pathology, Bergonié Institute, Bordeaux.,University Victor Ségalen, Bordeaux, France
| | - C Bouvier
- Aix Marseille University, Marseille.,Department of Pathology, Timone Hospital, Marseille
| |
Collapse
|
43
|
Macagno N, Fina F, Penel N, Bouvier C, Nanni I, Duffaud F, Rouah R, Lacarelle B, Ouafik L, Bonvalot S, Salas S. Proof of concept: prognostic value of the plasmatic concentration of circulating cell free DNA in desmoid tumors using ddPCR. Oncotarget 2018; 9:18296-18308. [PMID: 29719606 PMCID: PMC5915073 DOI: 10.18632/oncotarget.24817] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2017] [Accepted: 02/25/2018] [Indexed: 12/18/2022] Open
Abstract
Since desmoid tumors (DT) exhibit an unpredictable clinical course, with stabilization and/or spontaneous regression, an initial "wait-and-see" policy is the new standard of care-thus, the actual challenge is to identify early factors of progression. We present a method of detection of CTNNB1 mutations using a targeted digital droplet PCR (ddPCR) on cell-free DNA (cfDNA) extracted from blood samples of 31 DT patients. Furthermore, we analyzed the correlation between DT evolution and plasmatic concentration of total and mutated cfDNA at the time of diagnosis. Circulating copies of CTNNB1 mutants (ctDNA) were detected in the plasma of 6 patients (33%) but their concentration was not correlated with evolution of the tumor. Concentration of total cfDNA was higher in the plasma of patients with progressive desmoids (p = 0,0009). Using a threshold <900 copies/mL of plasma to detect indolent desmoid and a threshold >1375, it was possible to predict desmoid evolution for 65% of patients by measuring the quantity of circulating DNA in their plasma as early as the time of diagnosis. Albeit showing that the detection of CTNNB1 mutants is possible in the plasma of patients harboring a desmoid tumor, the results of this preliminary study raise the hypothesis that most of the circulating DNA detected in their plasma is derived from non-neoplastic cells, most likely normal neighboring tissues being actively invaded. Our results open the perspective of using cfDNA as a biomarker to predict prognosis at the time of diagnosis and assess tumor dynamics to optimize the treatment strategy.
Collapse
Affiliation(s)
- Nicolas Macagno
- Department of Pathology, Assistance Publique Hôpitaux de Marseille Timone Hospital, Marseille, France.,Aix-Marseille University, Medical Faculty, CRO2, UMR 911 (Equipe IV), Marseille, France
| | - Frédéric Fina
- Department of Pathology, Assistance Publique Hôpitaux de Marseille Timone Hospital, Marseille, France.,ID-Solutions, Grabels, France
| | - Nicolas Penel
- Department of General Oncology, Oscar Lambret Center, Lille, France
| | - Corinne Bouvier
- Department of Pathology, Assistance Publique Hôpitaux de Marseille Timone Hospital, Marseille, France.,Aix-Marseille University, Medical Faculty, CRO2, UMR 911 (Equipe IV), Marseille, France
| | - Isabelle Nanni
- Department of Molecular Oncology, Assistance Publique Hôpitaux de Marseille, Marseille, France
| | - Florence Duffaud
- Department of Oncology, Assistance Publique Hôpitaux de Marseille Timone Hospital, Marseille, France.,Aix-Marseille University, Medical Faculty, Marseille, France
| | - Raquel Rouah
- Department of Molecular Oncology, Assistance Publique Hôpitaux de Marseille, Marseille, France
| | - Bruno Lacarelle
- Department of Medical Biology, Assistance Publique Hôpitaux de Marseille Timone Hospital, Marseille, France
| | - L'houcine Ouafik
- Department of Molecular Oncology, Assistance Publique Hôpitaux de Marseille, Marseille, France
| | - Sylvie Bonvalot
- Department of Surgery, Institut Curie, PSL Univeristy, Paris, France
| | - Sébastien Salas
- Department of Oncology, Assistance Publique Hôpitaux de Marseille Timone Hospital, Marseille, France.,Aix-Marseille University, Medical Faculty, Marseille, France
| |
Collapse
|
44
|
Macagno N, Caselles K, Aubert S, Audard V, Gomez-Brouchet A, Galant C, Guinebretière JM, Karanian M, Larousserie F, Marie B, de Pinieux G, Bouvier C. Diagnostic des lésions osseuses riches en cellules géantes : démarche diagnostique et intérêt des nouvelles techniques complémentaires immuno-histochimiques et moléculaires. Ann Pathol 2018; 38:92-102. [DOI: 10.1016/j.annpat.2018.01.008] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2017] [Revised: 01/08/2018] [Accepted: 01/28/2018] [Indexed: 11/29/2022]
|
45
|
Galant C, Bouvier C, Larousserie F, Aubert S, Audard V, Brouchet A, Marie B, Guinebretière JM, de Pinieux du Bouexic G. [Histological diagnosis of bone tumors: Guidelines of the French committee of bone pathologists reference network on bone tumors (RESOS)]. Bull Cancer 2018. [PMID: 29540287 DOI: 10.1016/j.bulcan.2017.11.018] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
The management of patients having a bone lesion requires in many cases the realization of a histological sample in order to obtain a diagnosis. However, with the technological evolution, CT-guided biopsies are performed more frequently, often in outpatient clinics. Interpretation of these biopsies constitutes new challenges for the pathologists within the wide spectrum of bone entities. The purpose of the document is to propose guidelines based on the experience of the French committee of bone pathologists of the reference network on bone tumors (RESOS) regarding the indications and limitations of the diagnosis on restricted material.
Collapse
Affiliation(s)
- Christine Galant
- Service d'anatomie pathologique des cliniques universitaires Saint-Luc, 10, avenue Hippocrate, 1200 Bruxelles, Belgique.
| | - Corinne Bouvier
- Hôpital de la Timone 2/BMT, service d'anatomie et cytologie pathologiques et de neuropathologie ACPNP, 264, rue Saint-Pierre, 13385 Marseille cedex 05, France
| | - Frédérique Larousserie
- AP-HP hôpital Cochin, service d'anatomie et cytologie pathologiques, service de pathologie, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France
| | - Sébastien Aubert
- CHR-U centre de biologie-pathologie, anatomie et cytologie pathologiques, avenue Oscar-Lambret, 59037 Lille cedex, France
| | - Virginie Audard
- AP-HP hôpital Cochin, service d'anatomie et cytologie pathologiques, service de pathologie, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France
| | - Anne Brouchet
- CHU, pôle IUC oncopole, anatomie et cytologie pathologiques, 1, avenue Irène-Joliot-Curie, 31059 Toulouse cedex 9, France
| | - Béatrice Marie
- Laboratoire d'anatomie pathologique de l'hôpital central, 29, avenue du Maréchal-de Lattre-de-Tassigny, 54035 Nancy cedex, France
| | | | - Gonzague de Pinieux du Bouexic
- CHRU de Tours, hôpital Trousseau, unité d'anatomie et cytologie pathologiques, avenue de la République, 37044 Tours cedex 9, France
| | | |
Collapse
|
46
|
Fina F, Barets D, Colin C, Bouvier C, Padovani L, Nanni-Metellus I, Ouafik L, Scavarda D, Korshunov A, Jones DTW, Figarella-Branger D. Droplet digital PCR is a powerful technique to demonstrate frequent FGFR1 duplication in dysembryoplastic neuroepithelial tumors. Oncotarget 2018; 8:2104-2113. [PMID: 27791984 PMCID: PMC5356784 DOI: 10.18632/oncotarget.12881] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2016] [Accepted: 10/13/2016] [Indexed: 01/23/2023] Open
Abstract
Dysembryoplastic neuroepithelial tumors (DNT) share V600E mutation in the BRAF gene with other low grade neuroepithelial tumors (LGNTs). FGFR1 internal tandem duplication of the tyrosine-kinase domain (FGFR1-ITD), another genetic alteration that also leads to MAP kinase pathway alteration, has been previously reported in LGNTs by whole-genome sequencing. In the present study we searched for FGFR1-ITD by droplet digital PCR (DDPCR™) and for FGFR1 point mutations by HRM-sequencing in a series of formalin-fixed paraffin-embedded (FFPE) LGNTs including 12 DNT, 2 oligodendrogliomas lacking IDH mutation and 1p/19q co- deletion (pediatric-type oligodendrogliomas; PTOs), 3 pediatric diffuse astrocytomas (PDAs), 14 gangliogliomas (GGs) and 5 pilocytic astrocytomas (PAs). We showed by DDPCR™ that 5/12 DNT, but none of the other LGNTs, demonstrated FGFR1-ITD. In addition, these cases also accumulated phosphorylated-FGFR1 protein as shown by immunohistochemistry. FGFR1G539R point mutation was only recorded in one DNT that also showed FGFR1-ITD. Interestingly, these FGFR1 alterations were mutually exclusive from BRAFV600E mutation that was recorded in 13 LGNTs (3 DNTs, 1 PTO, 2 PDAs, 5 GGs and 2 PAs). Therefore, FGFR1 alteration mainly represented by FGFR1-ITD is a frequent event in DNT. DDPCR™ is an easy and alternative method than whole-genome sequencing to detect FGFR1-ITD in FFPE brain tumors, in routine practice.
Collapse
Affiliation(s)
- Frédéric Fina
- Assistance Publique Hôpitaux de Marseille (AP-HM), Hôpital Nord, Service de Transfert d'Oncologie Biologique, Laboratoire de Biologie Médicale Marseille, France
| | - Doriane Barets
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France
| | - Carole Colin
- Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France
| | - Corinne Bouvier
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France.,Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France
| | - Laëtitia Padovani
- APHM, Hôpital de la Timone, Service de Radiothérapie, Marseille, France
| | - Isabelle Nanni-Metellus
- Assistance Publique Hôpitaux de Marseille (AP-HM), Hôpital Nord, Service de Transfert d'Oncologie Biologique, Laboratoire de Biologie Médicale Marseille, France
| | - L'Houcine Ouafik
- Assistance Publique Hôpitaux de Marseille (AP-HM), Hôpital Nord, Service de Transfert d'Oncologie Biologique, Laboratoire de Biologie Médicale Marseille, France
| | - Didier Scavarda
- APHM, Hôpital de la Timone, Service de Neurochirurgie Pédiatrique, Marseille, France
| | - Andrey Korshunov
- Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - David T W Jones
- Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Dominique Figarella-Branger
- APHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France.,Aix-Marseille Université, Inserm, CRO2 UMR_S 911, Marseille, France
| |
Collapse
|
47
|
Bouvier C, Macagno N, Nguyen Q, Loundou A, Jiguet-Jiglaire C, Gentet JC, Jouve JL, Rochwerger A, Mattei JC, Bouvard D, Salas S. Prognostic value of the Hippo pathway transcriptional coactivators YAP/TAZ and β1-integrin in conventional osteosarcoma. Oncotarget 2018; 7:64702-64710. [PMID: 27608849 PMCID: PMC5323109 DOI: 10.18632/oncotarget.11876] [Citation(s) in RCA: 44] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2016] [Accepted: 08/01/2016] [Indexed: 11/25/2022] Open
Abstract
Introduction Currently, very few studies are available concerning the mammalian Hippo pathway in bone sarcomas. YAP/TAZ transcription co-activators are key downstream effectors of this pathway and may also have oncogenic properties. Additionally, recent in-vitro experiments showed that expression of β1-integrin promoted metastasis in osteosarcomas. This study investigated the expression of YAP/TAZ and β1-integrin in human osteosarcomas. Materials and methods We performed automated immunohistochemistry on tissue-microarrays (TMA) in which 69 conventional osteosarcomas biopsies performed prior to chemotherapy were embedded. Cellular localization and semi-quantitative analysis of each immunostain was performed using Immunoreactive Score (IRS) and correlated to clinico-pathological data. Results Cytoplasmic expression of β1-integrin was noted in 54/59 osteosarcomas (92%), with 33/59 cases (56%) displaying membranous staining. YAP/TAZ was expressed in 27/45 osteosarcomas (60%), with 14 cases (31%) showing cytoplasmic expression while 13 other cases (28%) displayed nuclear expression. No link was found between YAP/TAZ or β1-integrin expression and response to chemotherapy. In univariate analysis, YAP/TAZ immunoreactive score was pejoratively correlated with overall survival (p = 0.01). Expression of β1-integrin on cell membrane was also pejorative for OS (p = 0.045). In multivariate analysis, YAP/TAZ nuclear expression was an independent prognostic factor for PFS (p = 0.035). Conclusion this study indicates that β1-integrin and YAP/TAZ proteins are linked to prognosis and therefore could be therapeutic targets in conventional osteosarcomas.
Collapse
Affiliation(s)
- Corinne Bouvier
- Aix-Marseille University (AMU), Faculty of Medecine, CRO2, UMR 911 (Equipe IV), Marseille, France.,Department of Pathology, APHM, Timone Hospital, Marseille, France
| | - Nicolas Macagno
- Aix-Marseille University (AMU), Faculty of Medecine, CRO2, UMR 911 (Equipe IV), Marseille, France.,Department of Pathology, APHM, Timone Hospital, Marseille, France
| | - Quy Nguyen
- Aix-Marseille University (AMU), Faculty of Medecine, CRO2, UMR 911 (Equipe IV), Marseille, France
| | - Anderson Loundou
- Department of Public Health, Aix-Marseille University (AMU), Faculty of Medecine, EA 3270 Research Unit, Marseille, France.,Department of Research and Innovation, APHM, Timone Hospital, Support Unit for Clinical Research and Economic Evaluation, Marseille, France
| | - Carine Jiguet-Jiglaire
- Aix-Marseille University (AMU), Faculty of Medecine, CRO2, UMR 911 (Equipe IV), Marseille, France
| | - Jean-Claude Gentet
- Department of Pediatric Oncology, APHM, Timone Hospital, Marseille, France
| | - Jean-Luc Jouve
- Department of Pediatric Orthopaedic Surgery, APHM, Timone Hospital, Marseille, France
| | | | - Jean-Camille Mattei
- Aix-Marseille University (AMU), Faculty of Medecine, CRO2, UMR 911 (Equipe IV), Marseille, France.,Department of Adult Orthopaedic Surgery, APHM, Nord Hospital, Marseille, France
| | | | - Sébastien Salas
- Aix-Marseille University (AMU), Faculty of Medecine, CRO2, UMR 911 (Equipe IV), Marseille, France.,Department of Pathology, APHM, Timone Hospital, Marseille, France
| |
Collapse
|
48
|
Delteil C, Malissen N, Appay R, Magis Q, Aubert S, Bouvier C, Richard MA, Macagno N. [Chordoma cutis, an unusual clinical presentation of a rare neoplasm: Chordoma]. Ann Pathol 2018; 38:126-130. [PMID: 29449046 DOI: 10.1016/j.annpat.2018.01.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2017] [Revised: 12/06/2017] [Accepted: 01/08/2018] [Indexed: 11/26/2022]
Abstract
Chordoma cutis represents an unusual clinical presentation of a rare neoplasm. The involvement of skin or sub-cutaneous soft tissues can be the consequence of local infiltration or metastasis; the latter may occur several years following the initial diagnosis of chordoma and therefore, may pose a diagnosis challenge when the clinical history of the patient is unknown. The clinical forms, morphology, immuno-histochemical profile and the main differential diagnoses of chordoma cutis are presented here through an anatomoclinical case.
Collapse
Affiliation(s)
- Clémence Delteil
- Service d'anatomie pathologique et neuropathologie, CHU Timone, 264, rue Saint-Pierre, 13005 Marseille cedex 5, France.
| | - Nausicaa Malissen
- Service de cancérologie cutanée, CHU Timone, Assistance publique hôpitaux de Marseille (AP-HM), 13005 Marseille, France
| | - Romain Appay
- Service d'anatomie pathologique et neuropathologie, CHU Timone, 264, rue Saint-Pierre, 13005 Marseille cedex 5, France
| | - Quentin Magis
- Service de cancérologie cutanée, CHU Timone, Assistance publique hôpitaux de Marseille (AP-HM), 13005 Marseille, France
| | | | - Corinne Bouvier
- Service d'anatomie pathologique et neuropathologie, CHU Timone, 264, rue Saint-Pierre, 13005 Marseille cedex 5, France
| | - Marie-Aleth Richard
- Service de cancérologie cutanée, CHU Timone, Assistance publique hôpitaux de Marseille (AP-HM), 13005 Marseille, France
| | - Nicolas Macagno
- Service d'anatomie pathologique et neuropathologie, CHU Timone, 264, rue Saint-Pierre, 13005 Marseille cedex 5, France
| |
Collapse
|
49
|
Norton J, David M, Gandubert C, Bouvier C, Gutierrez LA, Frangeuil A, Macgregor A, Oude Engberink A, Mann A, Capdevielle D. Détection par le médecin généraliste des troubles psychiatriques courants selon l’auto-questionnaire diagnostique le Patient Health Questionnaire : dix ans après, le dispositif du médecin traitant a-t-il modifié la donne ? Encephale 2018; 44:22-31. [DOI: 10.1016/j.encep.2016.07.009] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2016] [Revised: 06/30/2016] [Accepted: 07/01/2016] [Indexed: 10/20/2022]
|
50
|
Gomez-Brouchet A, Illac C, Gilhodes J, Bouvier C, Aubert S, Guinebretiere JM, Marie B, Larousserie F, Entz-Werle N, Pinieux GD, Filleron T, Minard V, Minville V, Mascard E, Gouin F, Jimenez M, Ledeley MC, Piperno-Neumann S, Brugieres L, Redini F. Abstract B29: CD163-positive tumor-associated macrophages and CD8-positive cytotoxic lymphocytes are powerful diagnostic markers for therapeutic stratification of osteosarcoma patients in the French OS 2006 trial. Clin Cancer Res 2018. [DOI: 10.1158/1557-3265.sarcomas17-b29] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The French phase 3 trial (OS 2006) testing combining zoledronate (an osteoclast inhibitor) with chemotherapy and surgery did not improve the outcome of patients with osteosarcoma. To understand this unexpected result, the presence of infiltrating immune cells was investigated in 124 biopsies of patients enrolled in the trial. The percentage of CD68/CD163 tumor-infiltrating macrophages, CD8 lymphocytes, osteoclasts, and the PD1/PDL-1 checkpoint was assessed by immunohistochemistry. M1/M2 macrophage polarization was characterized by pSTAT1/CMAF staining. The expression of these biomarkers was correlated with clinical outcome. No statistical correlations were found with response to chemotherapy. High CD163 levels (>50% of cells per core; 43.8% of patients) were associated with CMAF nuclear expression and significantly correlated with greater overall survival (p=0.0025) and with longer metastasis progression-free survival (MPFS, p=0.0315) independently of diagnosis status (p=0.002). Only a trend was observed for patients with high CD68-positive cells (p=0.0582). CD8 staining was positive in >50% of cases with a median staining of 1%. Lower CD8 levels were associated with metastatic disease at diagnosis and only the presence of CD8-positive cells significantly correlated with improved overall survival in zoledronate-treated patients (p=0.0415). PD1/PDL-1 staining was negative in >80% of cases and was not correlated to prognosis. Finally, CD163-positive TAMs and CD8-positive cells (and not the PD1/PDL-1 checkpoint) are crucial predictive biomarkers in osteosarcoma. For the first time, we described a correlation between CD8-positive cells and zometa treatment. The immunohistochemical analysis of the microenvironment in osteosarcoma patient biopsies could represent a novel tool for therapeutic stratification.
Citation Format: Anne Gomez-Brouchet, Claire Illac, Julia Gilhodes, Corinne Bouvier, Sébastien Aubert, Jean-Marc Guinebretiere, Béatrice Marie, Frédérique Larousserie, Natacha Entz-Werle, Gonzague de Pinieux, Thomas Filleron, Véronique Minard, Vincent Minville, Eric Mascard, François Gouin, Marta Jimenez, Marie-Cécile Ledeley, Sophie Piperno-Neumann, Laurence Brugieres, Françoise Redini. CD163-positive tumor-associated macrophages and CD8-positive cytotoxic lymphocytes are powerful diagnostic markers for therapeutic stratification of osteosarcoma patients in the French OS 2006 trial [abstract]. In: Proceedings of the AACR Conference on Advances in Sarcomas: From Basic Science to Clinical Translation; May 16-19, 2017; Philadelphia, PA. Philadelphia (PA): AACR; Clin Cancer Res 2018;24(2_Suppl):Abstract nr B29.
Collapse
Affiliation(s)
| | - Claire Illac
- 1Dpt. Pathology, IUCT-Oncopole, Toulouse, France,
| | | | | | | | | | | | | | | | | | | | | | | | - Eric Mascard
- 12Dpt. Pediatric Orthopedic Surgery, Necker Hospital, Paris, France,
| | | | | | | | | | | | | |
Collapse
|